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Abbreviations 
aa  amino acids 
Ab antibody 
AD activation domain 
ALL acute lymphoblastic leukemia 
AML  acute myeloid leukemia 
Amp ampicillin 
AML-comp AML with complex aberrant karyotype 
AML_nk AML with normal karyotype 
ANTH domain AP180 N-terminal homology domain 
AP-2  clathrin adaptor protein complex 2 
APS  ammonium persulfate 
Aqua dest. water, deionized 
BD binding domain 
bp  base pairs 
BSA  bovine serum albumine 
cDNA  complementary DNA, synthetic DNA 
transcribed from a specific RNA through the 
action of the reverse transcriptase 
cfu  colony forming unit 
CME  clathrin mediated endocytosis 
CML chronic myelogenous leukemia 
CoIP  co-immunoprecipitation 
Conc concentration 
DAPI 4',6-diamidino-2-phenylindole  
dCTP Deoxycytosine triphosphate 
ddH2O  double distilled water 
DEPC diethylpyrocarbonate 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO  dimethylsulfoxide 
dGTP Deoxyguanosine triphosphate 
DMF Dimethylformamide 
DNA  deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DO drop out 
DTT dithiothreitol 
dTTP Deoxythymidine triphosphate 
ECFP Enhanced Cyan Fluorescent Protein 
EDTA ethylenediaminetetraacetic acid 
e.g.  example 
EGFP Enhanced Green Fluorescent Protein 
EST  expressed sequence tags 
EtBr Ethidium-bromide 
EtOH ethanol 
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EYFP Enhanced yellow fluorescent protein 
FAB French-American-British classification system 
for acute leukemia 
FBS Fetal bovine serum 
FCS Fetal calf serum 
g gram 
g relative centrifugal acceleration 
GAL Galactose 
GAL4 yeast transcription factor 
GAL4-AD GAL4 transcriptional activation domain 
GAL4-DBD GAL4 DNA binding domain 
GAL4-UAS GAL4 upstream activating sequence 
Gly Glycine 
GFP green fluorescent protein 
GST glutathione S transferase 
HEPES N-(2-Hydroxythyl) piperazine-N’-2-ethan 
sulphuric acid 
His Histidine 
HRP horse radish peroxidase 
hr(s)  hour(s) 
HSC Hematopoietic stem cell 
IPTG isopropyl β-D thiogalactoside 
KAc Potassium acetate 
kb kilobase 
KCl Potassium chloride 
kDa kilodalton 
KH hnRNP K homology domain 
KH2PO4 Potassium dihydrogenphosphate 
l liter 
LacZ E. coli gene encoding beta-galactosidase 
LB Luria Bertani bacterial medium 
Leu = L Leucine 
LiAc lithium acetate 
LIM Lin11, Isl-1 and Mec-3 domain 
Lys = K  Lycine 
M Molar 
m milli (1 x 10-3) 
MCS multiple cloning site 
Met = M Methionine 
MgCl2 Magnesium chloride 
MgSO4 Magnesium sulfate 
min minute(s) 
ml milliliter 
MLL Myeloid/lymphoid or mixed-lineage leukemia 
mM Milli Molar 
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MOPS 3-N-morpholino-propanesulfonic acid 
mRNA messenger RNA 
MW Molecular weight 
n Nano (1 x 10-9) 
NaAC sodium acetate 
NaOH sodium hydroxide 
NaH2PO4 sodium dihydrogenphosphate 
Na2HPO4 disodium hydrogenphosphate 
(NH4)2SO4 ammonium sulfate 
NLS nuclear localization signal 
nt nucleotide 
O/N overnight 
ºC degree Celsius 
OD optical density 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PEG polyethylenglycol 
Pen/Strep Penicillin/Streptomycin 
PFA paraformaldehyde 
pg pico gram 
PHD plant homeodomain 
Phe = F Phenylalanine 
PMSF Phenylmethylsulfonyl fluoride 
PtdIns(4,5)P2 phosphatidylinositol-4,5-bisphosphate 
RNA ribonucleic acid 
RNAse  ribonuclease  
Rpm revolutions Per Minute 
RPMI Roswell Park Memorial Institute culture 
medium 
RT room temperature 
SD synthetic defined Dropout medium 
SDS sodium dodecylsulfate 
sec second(s) 
Taq Thermus aquaticus (-Polymerase) 
TBS tris buffered saline 
TE tris-EDTA buffer 
TEMED N,N,N’,N’-Tetramethylethylendiamine 
Thr = T Threonine 
Tris trishydroxymethylaminomethane 
Trp = W Tryptophan 
tot. total 
Tm melting temperature 
Tyr = Y Tyrosine 
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U unit 
UTR untranslated region 
UV ultraviolet  
V volts 
Val = V Valine 
vector plasmid or phage chromosome used to carry 
cloned DNA segment 
vol. volume 
v/v volume per volume ratio 
w/v weight per volume ratio 
WB Western blot 
x g gravity (9.81 m/s2) 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside 
Y2H yeast two hybrid 
YFP yellow fluorescent protein 
YPD yeast extract, peptone, dextrose 
μ micro (1 x 10-6) 
μl micro liter 
μm micro meter 
μM micro molar 
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1 Introduction 
1.1 Hematopoiesis  
1.1.1 Hematopoietic stem cell 
Our body generates billions of blood cells every day. Hematopoiesis, the formation of red 
and white blood cells, begins already in the embryonic yolk sac. During the development 
of the human fetus, hematopoietic stem cells (HSC) migrate from the yolk sac to the fetal 
liver and thereafter to the spleen. After the 7th month of gestation the differentiation of 
HSCs in the bone marrow becomes the major location of hematopoiesis. HSCs consists 
of two subpopulations -one with short-term repopulation ability (<10 weeks) and the 
second population with a long-term repopulating ability that lasts the lifetime of an 
organism (Morrison S. and Weissman I., 1994). There are two standards for defining a 
cell as a normal stem cell: it must have the ability (1) to self-renew and (2) to 
differentiate into the various blood cells (Till J.E. and McCullough E.A., 1961; 
Weissman I. L., 2000). Early in hematopoiesis the HSC differentiates either into a 
lymphoid progenitor cell or into a myeloid progenitor cell. Progenitor cells are cells that 
have lost the capacity to self-renew and are destined to a particular cell lineage. The 
lymphoid progenitor gives rise to B-, T- and natural killer (NK) cells, while the myeloid 
progenitor give rise to red blood cells (erythrocytes), white blood cells (neutrophils, 
eosinophils, basophils, monocytes, mast cells) and megakaryocytes. In figure 1.1 a model 
of the differentiation pathways of the hematopoietic system is shown. 
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Figure 1.1 The hematopoietic system.The HSC differentiates into the common lymphoid progenitor 
(CLP) or into the common myeloid progenitor (CMP). The CMP differentiates in turn into red blood cells, 
white blood cells and megakaryocytes. The CLP differentiates into B-, T- and NK cells.  
The physiological function of hematopoietic stem cells is to replace blood cells that were 
lost in illness or trauma, and in normal cell turnover. Under normal conditions stem cells 
can be in a quiescent state for a longer time period, however once they exit this state they 
start to self renew or differentiate to generate needed progenies (McCulloch E. and Till 
J.E., 2005; Moore M. et al., 2006; Weissman I. L., 2000). 
Stem cell niche 
It is an evolutionarily conserved phenomenon that stem cells interact with their micro 
environment- the so called stem cell niche, to establish and maintain their properties 
(Fuchs E. et al., 2004). To be considered a stem cell niche, the environment has to enable 
the stem cells to reproduce or self renew (Scadden D., 2006). Recently it has been shown 
that osteoblasts, the bone-forming cells, are essential regulatory components of the HSC 
niche in the bone marrow compartment that influence HSC function through Notch 
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signaling (Calvi L., 2006; Stier S. et al., 2005). Once the stem cell compartment is 
formed in a tissue the stem cells often go into a quiescent state. This is for example the 
case when HSC that express the tyrosine kinase receptor Tie2 adhere to osteoblasts in the 
bone marrow niche. The interaction of Tie2 and its ligand angiopoietin-1 (Ang-1) results 
in HSCs tightly adhering to the stromal cells, which in turn leads to the maintenance of 
their long term repopulating activity of HSC (Suda T. et al., 2005). As the HSC 
progressively mature they lose contact with the stromal cells and start to proliferate. They 
migrate towards the central bone marrow cavity where they differentiate and proliferate 
and finally as mature blood cells they enter the blood vessels.  
Self renewal and leukemogenesis 
There is increasing evidence that the Notch, Hedgehog and Wnt pathways, that control 
many developmental processes, also regulate the self-renewal of hematopoietic 
progenitors and stem cells. These pathways have also been shown to be deregulated in 
cancers (Bhardwaj G. et al., 2001; Reya T. et al., 2001; Varnum-Finney B. et al., 2000) as 
shown in figure1.2. 
 
Figur 1.2 Signaling pathways regulating self renewal and stem cells. Notch, Hedgehog and Wnt 
pathways regulate developmental processes, self-renewal of hematopoietic progenitors and stem cells, and 
have been shown to be involved in cancers when deregulated (Picture from Reya, 2001). 
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In the case of Wnt signaling, the Wnt proteins are produced by HSCs themselves but also 
by the surrounding microenvironment (Rattis F.M. et al., 2004), implicating that Wnt can 
modulate HSC indirectly by influencing the microenvironment. Since normal stem cell 
and cancer cell share the ability to self renew (Al-Hajj M. and Clarke MF., 2004; Bonnet 
D. and Dick J., 1997) it is reasonable to assume that newly arising cancer cell use the 
machinery for self-renewing cell division that is used by stem cells for their own ends. 
There are two reasons to believe that stem cells themselves are the target of 
transformation: (1) stem cells already have self-renewal capacity and (2) self-renewing- 
stem cells often persist for long periods of time, instead of dying after short periods of 
time like many mature cells in highly proliferative tissues. This means that stem cells 
have the opportunity and time to accumulate the mutations that are required for malignant 
transformation.  
1.2 Chromosomal translocation 
Nowell and Hungerford discovered in 1960s a small acrocentric chromosome that was 
very often observed in association with chronic myeloid leukemia (CML) (Nowell and 
Hungerford, 1960). It was named the Philadelphia chromosome and was one of the first 
chromosomal abnormalities to be associated with a human cancer. The nature of this 
abnormality was unclear but it was assumed that a loss of chromosomal material from 
one of the small G-group chromosomes had occurred and that this loss was somehow 
associated with the development of leukemia. Following this discovery, recurring 
chromosomal abnormalities and the discovery that the Philadelphia chromosome in CML 
was the result of a balanced chromosomal translocation (Rowley J.D., 1973) led to an 
enormous increase in our understanding of the genetic changes that occur in leukemic 
cells. At the cytogenetic level most chromosome translocations in leukemia arise in 
hematopoietic stem cells and are reciprocal, stable and balanced (Zhang Y. and Rowley 
J., 2005). In balanced chromosomal translocations, genetic material between two non-
homologues chromosomes is exchanged (fig 1.3). 
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Figure 1.3 Balanced chromosomal translocation. The small arrows indicate the breakpoints. 
Such balanced translocations can have either of two consequences: (1) the juxtapposition 
of a coding region from one gene with a promoter of another gene leading to deregulated 
gene expression or (2) the fusion of two coding regions which creates a new chimaeric 
gene that encodes for a fusion protein (Rowley J.D., 1999; Rowley J.D., 2000; Rowley 
J.D., 2001). A classic example of the first consequence is the first molecularly 
characterized translocation t(8;14) that causes Burkitt’s lymphoma (Zech L. et al., 1976). 
The translocation juxtapposes the immunoglobulin heavy chain (IGH) promoter region to 
the MYC coding sequence resulting in abnormal expression of the MYC oncogene as 
seen in figure 1.4. 
 
Figure 1.4 Malignant transformation-1.The juxtaposition of a coding region from one gene with a 
promoter of another gene inducing altered expression of Gene B. (Adapted of Rowley, 2001)  
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The examples for the second consequence is the t(9;22)(q34;q11) translocation which 
leads to a fusion between the breakpoint cluster region (BCR) gene and the Abelson 
tyrosine kinase (ABL) gene resulting in the production of the BCR/ABL fusion protein, 
figure 1.5. 
 
Figure 1.5 Malignant transformation-2. Fusion of two coding regions that create a new chimaeric gene 
that encodes a new fusion protein. (Picture adapted from Rowley, 2001) 
The association of particular chromosomal translocations with specific subtypes of 
leukemia and lymphomas led to a strong research activity in this field and today leukemia 
and lymphoma are the most extensively characterized human malignant diseases. As a 
result of this activity a network of different fusion genes has emerged showing that some 
genes are involved in more than one translocation forming fusion genes with several 
partner genes. The most prominent genes involved in more than one translocation in this 
network are the RUNX1 (AML1), ETV6 and MLL genes, which have been shown to play 
central roles in the pathogenesis of different leukemias (Bohlander S.K. et al., 2000). 
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1.3 The CALM/AF10 fusion gene 
1.3.1 CALM, AF10 and the CALM/AF10 fusion 
The t(10;11)(p13;q14) translocation was first characterized at the molecular level in the 
human monocytic cell line U937 (Dreyling M. et al., 1996). This balanced translocation 
results in a fusion of CALM on chromosome 11, band q14, to AF10 on chromosome 10 
band p13 as shown in figure 1.6. 
 
Figure 1.6 The CALM/AF10 and AF10/CALM fusion genes.The distal part of the short arm of 
chromosome 10 is fused to the proximal long arm of chromosome 11 resulting in the formation of an 
AF10/CALM fusion gene at the breakpoint. The distal part of the long arm of chromosome 11 is fused to 
the proximal part of the short arm chromosome 10 resulting in the formation of the CALM/AF10 fusion 
gene.  
The breakpoint in the CALM gene is located at the C-terminus of the gene and the 
breakpoint in AF10 is located near the N-terminus of AF10. The CALM/AF10 fusion 
contains almost the complete open reading frames of both the CALM and AF10 genes 
(Dreyling M. et al., 1996), whereas the AF10/CALM fusion only encodes for a truncated 
AF10 protein consisting of 84 amino acids as seen in figure 1.7. 
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Figure 1.7 Scheme of AF10 and CALM proteins, respectively AF10/CALM and CALM/AF10 
translocations.Breakpoints in the protein in U937 cell line are indicated by arrows, and breakpoints found 
in cells from patients are indicated by triangles. It can be seen that CALM/AF10 translocation contains 
almost the whole AF10 and CALM gene while AF10/CALM translocation contains the small leftover parts. 
PHD: plant homeodomain zinc fingers; NLS: nuclear localization signal; AT: AT-hook motif; OM: 
octapeptide motif; LZ: leucine zipper; Q: glutamic acid rich domain; ANTH: AP180 N-terminal homology 
domain. 
Due to the location of the breakpoints in CALM and AF10 the reciprocal fusion mRNAs 
encode fusion proteins of unequal size. Analysis of the breakpoint region in 
t(10;11)(p13;q14) leukemia showed three different breakpoints in CALM and four 
breakpoints in the AF10 gene with no apparent correlation between the location of the 
breakpoints and the phenotype or outcome of disease (Bohlander S.K. et al., 2000; 
Kumon K. et al., 1999). The CALM/AF10 fusion transcript has mainly been identified in 
T-cell acute lymphoblastic leukemia (ALL), undifferentiated acute myeloid leukemia 
(AML) (FAB M0 or M1) and in malignant lymphoma and has a poor prognosis (Dreyling 
M. et al., 1998; Kumon K. et al., 1999; Narita M. et al., 1999). Later CALM/AF10 
translocations were also observed in more differentiated AML subtypes (FAB M4, M5 
1 Introduction 
 
 9 
and M7) (Abdou S.M. et al., 2002; Carlson K. et al., 2000; Jones L.K. et al., 2001; 
Nakamura F. et al., 2003; Salmon-Nguyen F. et al., 2000). 
Most t(10;11)(p13;q14) translocations generate CALM/AF10 as well as the AF10/CALM 
fusion transcripts. However, AF10/CALM transcripts are not detected in all leukemia 
samples indicating that it is probably the CALM/AF10 fusion transcript that directs the 
transformation process (Carlson K. et al., 2000). Desphande et al, showed that the 
expression of the  CALM/AF10 fusion protein is sufficient to cause an aggressive 
biphenotypic leukemia in a murine bone marrow transplantation model (Deshpande A. et 
al., 2006 ). 
The AF10 gene (ALL 1 fused gene from chromosome 10), was first identified as a fusion 
partner of MLL in 3 AML patients with a t(10;11)(p12;q23) translocation (Chaplin T. et 
al., 1995). In 1996, Dreyling et al described the second translocation involving AF10- the 
CALM/AF10 translocation. The AF10 gene is located on chromosome 10 band p12 and 
encodes a 1,027 amino acids long protein. The AF10 gene encodes a putative 
transcription factor containing N-terminally two LAP/PHD (Leukemia Associated 
Protein/Plant Homeo Domain) zinc finger motifs, three extended LAP/PHD fingers, a 
nuclear localization signal (NLS), an AT-hook domain, an octapeptide motif (OM), a 
leucine zipper (LZ) motif and a glutamic acid rich region (Q rich region). The Drosophila 
homologue of AF10, alhambra, has been suggested to play a role in heterochromatin-
mediated transcriptional silencing (Debernardi S. et al., 2002; Linder B. et al., 2001; 
Linder B. et al., 2000; Perrin L. et al., 2003; Perrin L. and Dura J.M., 2004; Saha V. et al., 
1995). 
CALM was first identified as the fusion partner of AF10 in the human monocytic cell line 
U937 that harbors the t(10;11)(p13;q14) translocation (Dreyling M. et al., 1996). The 
clathrin assembly lymphoid myeloid leukemia protein (CALM) is the ubiquitously 
expressed homologue of the neuron-specific protein AP180 (Tebar F. et al., 1999). CALM 
is located on chromosome 11 band q14 and encodes a 652 amino acid long protein. The 
homologous proteins of CALM: LAP (in Drosohophila melanogaster) and Unc11 (in 
Caenorhabditis elegans) are both implicated in clathrin-mediated endocytosis (CME). 
Mutations of LAP and Unc11 suggest that these proteins play a role in the regulation of 
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endocytic vesicle size (Kalthoff C. et al., 2002; Meyerholz A. et al., 2005; Nonet M. et 
al., 1999). It has also been shown that CALM plays a role in clathrin mediated 
endocytosis by promoting the assembly of clathrin into clathrin cages and taking part in 
the initial stage of coated pit formation and invagination together with clathrin, AP-2 and 
PtdIns(4,5)P2 containing membranes (Ford M. et al., 2001; Kim H.L. and Kim J.A., 2000; 
Kim J.A. and Kim H.L., 2001; Meyerholz A. et al., 2005; Tebar F. et al., 1999). This 
process is probably mediated by binding of phosphoinositides through the CALM Epsin 
N-terminal homology (ENTH) domain and binding of clathrin through the CALM C-
terminal region. The CALM- clathrin interaction has been shown, in vitro, to promote the 
assembly of clathrin triskelia into clathrin cages (Ford M. et al., 2001; Kim H.L. and Kim 
J.A., 2000). Both overexpression and down regulation of CALM have been shown to 
inhibit CME and impair the trafficking of receptors between the trans golgi network and 
endosomes (Meyerholz A. et al., 2005; Tebar F. et al., 1999). Point mutations in the 
mouse homologue Picalm were shown to cause abnormalities in hematopoiesis, iron 
metabolism and bone growth (Klebig M. et al., 2003). 
However, many aspects of the function of CALM or the leukemogenic CALM/AF10 
fusion protein are unknown. We chose to learn more about the function of CALM by 
searching for CALM interacting proteins with a yeast two hybrid screen. One of the 
interesting proteins discovered in our screen was the FHL2 protein (four and a half LIM 
domain protein 2). 
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2 Material and Methods  
2.1 Material 
2.1.1 Reagents 
1-kb-DNA Ladder 
 
Invitrogen, Karlsruhe, Germany 
β-Mercaptoethanol Sigma, Taufkirchen, Germany 
Acetic acid Merck, Darmstad, Germany 
Acrylamid Rotiphorese® Gel 30 (37, 5:1) Carl Roth, Karlsruhe, Germany 
Agar Carl Roth, Karlsruhe, Germany 
Agarose ICN Biomedicals Inc. 
Amino acids (yeast two-hybrid) Sigma, Taufkirchen, Germany 
Ammonium persulfate (APS) Sigma, Taufkirchen, Germany 
Ampicillin Na-Salt Pan Biotech, Aidenbach, Germany 
BigDye™ terminator mix PE Applied Biosystems, Foster City, CA 
Boric acid Carl Roth, Karlsruhe, Germany 
Bovine serum albumin Sigma, Taufkirchen, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Calcium chloride (CaCl2) Sigma, Taufkirchen, Germany 
Coomassie® stain solution BioRad, Hercules, CA 
D(+)-Glucose-Monohydrate Merck, Darmstadt, Germany 
Dakocytomation Mounting Medium DakoCytomation, Hamburg, Germany 
DAPI- 4',6-diamidino-2-phenylindole Sigma, Taufkirchen, Germany 
d2H2O Millipore, Eschborn, Germany 
Deoxyribonuclease I, Amplification Grade Invitrogen, Karlsruhe, Germany 
Diethyl Pyrocarbonate (DEPC) Sigma, Taufkirchen, Germany 
Dimethyl formamide (DMF) Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Carl Roth, Karlsruhe, Germany 
dNTP Set, PCR Grade Invitrogen, Karlsruhe, Germany 
DPBS Pan Biotech, Aidenbach, Germany 
Dulbecco´s Modified Eagle medium (DMEM), Pan Biotech, Aidenbach, Germany 
ECL™ Plus Western Blotting Detection Reagent Amersham, Freiburg, Germany 
ECL™ Western Blot Detection reagents Amersham, Freiburg, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Fetal bovine serum (FBS) Gibco Invitrogen cell culture, Karlsruhe, Germany 
Formaldehyde 37% Carl Roth, Karlsruhe, Germany 
Formamide Carl Roth, Karlsruhe, Germany 
Glutathione-Agarose Sigma, Taufkirchen, Germany 
Glycerin 87% neoLab, Heidelberg, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Merck, Darmstadt, Germany 
Herring Testes Carrier DNA denatured  DB Biosciences Clontech, Heidelberg, Germany 
Hydrochloridric acid 37% Merck, Darmstadt, Germany 
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Hydrogen peroxide (H2O2) solution 35%  Merck, Darmstadt, Germany 
IPTG Roche, Mannheim, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
Kanamycin Pan Biotech, Aidenbach, Germany 
Klenow Fragment MBI Fermentas, St. Leon-Rot, Germany 
L-Glutamine  Pan Biotech, Aidenbach, Germany 
Lithium acetate Sigma, Taufkirchen, Germany 
Magnesium Sigma, Taufkirchen, Germany 
Methanol Merck, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
MOPS (3-(N-Morpholino)-propanesulfonic acid)   Carl Roth, Karlsruhe, Germany 
NP40 (Nonidet P-40) Roche, Mannheim, Germany 
Oligo (dT)12-18 Primer Invitrogen, Karlsruhe, Germany 
PanScript DNA Polymerase Pan Biotech, Aidenbach, Germany 
Paraformaldehyde Electron Microscopy Sciences, Hatfield, USA 
Penicillin/streptomycin Pan Biotech, Aidenbach, Germany 
Pepstatin Sigma, Taufkirchen, Germany 
Peptone, meat pancreatic digested Merck, Darmstadt, Germany 
Phenol/chloroform/isoamyl (25:24:1) Invitrogen, Karlsruhe, Germany 
Phenylmethylsulfonylfluorid (PMSF) Sigma, Taufkirchen, Germany 
Platinum® Taq DNA Polymerase Invitrogen, Karlsruhe, Germany 
Polyethylenglycol (PEG) 4000 Merck, Darmstadt, Germany 
Potassium acetate (KAc) Calbiochem, San Diego, USA 
Potassium chloride (KCl) Calbiochem, San Diego, USA 
Protein A-Agarose Roche, Mannheim, Germany 
Protein G-Agarose Roche, Mannheim, Germany 
Proteinase inhibitor cocktail Sigma, Taufkirchen, Germany 
Proteinase K Sigma, Taufkirchen, Germany 
Restriction enzymes MBI Fermentas, Germany 
Restriction enzymes NewEngland Biolabs, Schwalbach, Germany 
Ribonuclease A MBI Fermentas, Sigma or Qiagen, Germany 
RNA Ladder, High Range MBI Fermentas, St. Leon-Rot, Germany 
RNA polymerase Roche, Mannheim, Germany 
RNase Away Carl Roth, Karlsruhe, Germany 
RNaseOUT™ Recombinant Ribonuclease Inhibitor Invitrogen, Karlsruhe, Germany 
Roswell Park Memorial Institute culture 
Medium (RPMI 1640) 
Pan Biotech, Aidenbach, Germany 
Roti®-Fect transfection reagent Carl Roth, Karlsruhe, Germany 
SDS- Sodium dodecyl sulfate Carl Roth, Karlsruhe, Germany 
SeeBlue® Plus2 pre-stained standard Invitrogen, Karlsruhe, Germany 
Shrimp Alkaline Phosphatase (SAP)l MBI Fermentas, St. Leon-Rot, Germany 
Sodium acetate, Anhydrous (NaAC) Calbiochem, San Diego, USA 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium deoxycholate Sigma, Taufkirchen, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium phosphate dibasic anhydrous (Na2HPO4) Sigma, Taufkirchen, Germany 
Sodium phosphate monobasic monohydrate (Na2HPO4) Calbiochem, San Diego, USA 
Sucrose Sigma, Taufkirchen, Germany 
Sybr Green Roche, Mannheim, Germany 
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SuperScript™ II RNase H- Reverse Transcriptase Invitrogen, Karlsruhe, Germany 
T4 DNA Ligase NewEngland Biolabs, Schwalbach, Germany 
Trichloroacetic acid (TCA) Carl Roth, Karlsruhe, Germany 
Tris- trishydroxymethylaminomethane Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Trypsin-EDTA  Gibco™, Germany 
Tween® 20 Sigma, Taufkirchen, Germany 
X-α- gal Clontech, Heidelberg, Germany 
Yeast extract Sigma, Taufkirchen, Germany 
Yeast nitrogen base without amino acids Difco, Detroit MI, USA 
2.1.2 Material and Kits 
Blotting paper GB003 and GB002 Schleicher & Schuell, Dassel, Germany 
Coverslips Menzel-Gläser®, Braunschweig, Germany  
Cryotube™ vials Nalge Nunc Internacional, Denmark 
DNeasy®Tissue Kit (50) Qiagen, Hilden, Germany 
Dual-Luciferase® Reporter Assay System Promega, Mannheim, Germany 
Electroporation cuvettes 2mm EquiBio, Kent, UK 
Endofree® Plasmid Maxi kit (10) Qiagen, Hilden, Germany 
Eppendorf tubes Eppendorf, Hamburg, Germany 
Filter 0.22μm Millipore, Belford, USA 
Genomed Plasmid Mega Kit Genomed, St. Louis, USA 
Glass beads  Sigma, Taufkirchen, Germany 
Glassware  Schott, Jena, Germany 
Hybond-N nylon membranes Amersham, Freiburg, Germany 
Hybond™ ECL™ nitrocellulose membrane Amersham, Freiburg, Germany 
Hypercassete™ 18x24 cm Amersham, Freiburg, Germany 
Hyperfilm ECL high performance Amersham, Freiburg, Germany 
JETSTAR MEGA Cartridge Genomed, Bad Oeynhausen, Germany 
Luminometer tube (Disposable Cuvettes 12 mm x 50 
mm) 
Promega, Mannheim, Germany 
Microcentrifuge tubes (1.5 ml) Eppendorf, Hamburg, Germany 
Microscope slides Menzel-Gläser®, Braunschweig, Germany 
Mitsubishi thermal papervideo-printer Mitsubishi, Hatfield, UK 
Nescofilm sealing film Carl Roth, Karlsruhe, Germany 
Pipette tips Carl Roth, Karlsruhe, Germany 
Plastic cuvettes for OD Carl Roth, Karlsruhe, Germany 
Plastic ware for cell culture Greiner Labortechnik, Frickenhausen, Germany 
Plastic ware for cell culture Sarstedt, Nümbrecht, Germany 
Plastic ware for cell culture Corning, USA 
Qiagen Gelextraction Kit Qiagen, Hilden, Germany 
Qiagen RNEasy Mini Kit Qiagen, Hilden, Germany 
Qiagen Midi Kit Qiagen, Hilden, Germany 
Qiagen EndoFree Maxi Kit Qiagen, Hilden, Germany 
QIAquick columns Qiagen, Hilden, Germany 
Qiashredder™ columns Qiagen, Hilden, Germany 
RNeasy™ mini kit Qiagen, Hilden, Germany 
Surgical blades Feather Safety Razor Co. Med. Div., Japan 
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Syringe  Braun, Melsungen, Germany 
2.1.3 Laboratory equipment 
Axioplan 2 Imaging microscope Carl Zeiss, Jena, Germany  
AxioCam HR digital camera Carl Zeiss, Jena, Germany 
Axiovert 200M microscope Carl Zeiss, Jena, Germany 
BioPhotometer 6131 Eppendorf, Hamburg, Germany 
Centrifuge 5417 C Eppendorf, Hamburg, Germany 
Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Cryotome CM 1850 Leica Microsystems, Wetzlar, Germany 
Electroporator (Easyject Prima)  EquiBio Peqlab, Erlangen, Germany 
Gel Air™ Drying System BioRad Laboratories, Hercules, CA 
Genetic Analyzer automated sequencer ABI PRISM 310 PE Applied Biosystems, Foster City, CA 
GS Gene Linker™ UV Chamber BioRad Laboratories, Hercules, CA 
Cell Culture Incubators Heraeus Instruments, Langenselbold, Germany 
Innova™ 4400 Incubator Shaker New Brunswick Scientific, Nürtingen, Germany 
Orion Microplate Luminometer Berthold Detection System 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Trans-Blot® SD Semi -Dry Transfer Cell BioRad Laboratories, Hercules, CA 
X-Ray Automatic Processor Curix 60 Agfa, Köln Germany 
2.1.4 Software 
Microsoft Office 2003 (Microsoft Corporation, USA) was used for text editing, table 
calculations and graphic images, Adobe Reader 7.0 (Adobe Systems, Mountain View, 
U.S.A) was used to convert documents into PDF format. Pictures were processed with 
Adobe Photoshop CS3 (Adobe Systems, Mountain View, U.S.A.). The Vector™ NTI 
Suite 9 (Oxford Molecular Group) was used for sequence analysis and primers design. 
The Leica Software was used for confocal imaging (Leica Microsystems, Germany).  
2.1.4.1 R program 
R (Bell Laboratories) is an object oriented program for statistical computing and 
graphics, written initially by Robert Gentleman and Ross Ihaka at Statistics Department 
of the University of Auckland, New Zealand. R can be used to analyze probe sets from 
micro array data. R is a free open source environment. Its strength is the graphical 
facilitiy that produce publication-quality graphs which can include mathematical 
symbols. 
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2.1.5 Buffers and Solutions 
All buffers and solution were prepared with d2H2O, unless they had to be RNase-free, in 
which case they were prepared with DEPC-treated-H2O.  
Ampicillin stock 
 
100 mg/ml Ampicillin  
Aqua bidest. 
Sterilized by filtration. Aliquots 1 ml; stored -20°C 
Ammonium chloride solution 0.8% 
0.1 mM 
NH4Cl in sterile water 
EDTA 
Blue Juice loading buffer (DNA) 65% 
10 mM 
10 mM 
0.3% 
Sucrose 
Tris/HCl pH 7.5 
EDTA 
Bromophenol blue 
Storage at room temperature (RT) 
Blocking milk solution 1 x 
5% 
0.05% 
TBS 
milk powder 
Tween 20 
DEPC-H2O 0.01% Diethyl pyrocarbonate (DEPC) in d2H2O 
Mix well, incubate O/N and autoclave 
Electrophoresis running buffer 
 
250 mM 
2 M 
1% 
Tris HCl, pH 8,5 
glycin 
SDS 
P1 and E1 resuspension buffer 50 mM 
10 mM 
100 μg/mL 
Tris/HCl pH 8.0 
EDTA 
RNAse A 
Storage at 4°C 
P2 and E2 lyses buffer 200 mM 
1% 
NaOH 
SDS 
Autoclave, storage at RT 
P3 and E3 neutralization buffer 3 M Potassium acetate pH5.5 (with acetic acid) 
Autoclave, storage at RT 
E4 100 mM 
600 mM  
0.15%  
Potassium acetate (pH 5.0 with acetic acid) 
NaCl 
Triton X-100 
E5 100 mM 
800 mM 
Sodium acetate(pH 5 with acetic acid) 
NaCl 
E6 100 mM 
1500mM 
Sodium acetate  
NaCl 
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Gel fixation solution  20% 
10% 
methanol (v/v) 
acetic acid (v/v) 
40% Glucose 40% w/v 
(400g) 
 
D-(+)-Glucose  
Fill up to 1l of d2H2O 
Autoclave 
GST buffer 100 mM  
25 mM 
0.1% 
NaCl 
Tris pH 7.5 
NP-40 
IP buffer  0.1 % NP-40 
PBS 
Kanamycin stock 
 
50mg/ml Kanamycin  
Aqua bidest. 
Sterilized by filtration. Aliquots 1 ml; stored at -20°C
Lyses solution for yeast cells 10 mM 
1 mM 
100 mM 
2% 
1% 
Tris/HCl pH 8.0 
EDTA 
NaCl 
Triton X-100 
SDS 
2x Lämmli sample buffer 10% 
6% 
20% 
0.2 mg/ml 
0.025X 
β-mercaptoethanol 
SDS 
Glycerol 
Bromophenol blue 
Lämmlie stacking buffer (optional) 
Store up to 2 month at RT 
2.5x Lämmli stacking buffer 0.3 M 
0.25% 
Tris/HCl pH 6.8 
SDS 
Store up to 1 month at 4°C 
NETN buffer  
 
150 mM 
20 mM 
1 mM 
0.5% 
NaCl  
Tris/HCl pH 8.0 
EDTA pH 8.0 
Triton X-100 
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Buffer A for cytoplasmic extract 
 
 
20 mM  
10 mM 
3 mM  
1% 
10%  
0.2 mM  
HEPES 
NaCl 
MgCl2 
NP 40 
Glycerol 
EDTA 
PBS-DEPC 30 ml 
15 ml 
955 ml 
5 M NaCl 
1 M Sodium phosphate buffer pH 7.3 
DEPC-H2O 
PEG/LiAc solution 8 vol. 
1 vol. 
1 vol.  
50% PEG 4000 
10X TE buffer 
10X LiAc 
10x LiAc solution 1 M Lithium acetate 
Adjust to pH 7.5 with acetic acid and autoclave 
2%  PFA 1 ml 
4 ml  
PFA (Paraformaldehyde) 
PBS 
Phosphate buffer saline (PBS) 140 mM 
5.4  mM 
9.7  mM 
2     mM 
800 ml 
NaCl  
KCl  
Na2HPO4 x 2H2O 
KH2PO4 
d2H2O 
adjust pH 7.4 with HCl,  
complete to 1 l vol. and autoclave 
RIPA buffer 1X 
1% 
0.5% 
0.1% 
10XPBS 
Triton X-100 
Sodium deoxycholate 
SDS 
RNA sample buffer (325 µl) 75 µl 
45 µl 
180 µl 
25 µl 
Formaldehyde 37% 
10X MOPS RNA running buffer 
Formamide 
Ethidium bromide (1 µg/µl) 
RNase solution (TNT) 10 mM 
0.5 M 
0.1% 
Tris/HCl pH 7.5 
NaCl 
Tween® 20 
in d2H2O 
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Rödel Mix 
 
1.85M 
7.4% 
20 mM 
641 μl 
NaOH    
β-mercaptoethanol    
200mM PMSF   
d2H2O      
 
10x MOPS RNA running buffer 0.2M  
20 mM 
10mM 
 
MOPS,  
NaAC 
EDTA 
Add DEPC-H2O to complete 1 l vol., adjust to pH 
7.0. Filter sterile and store at RT protected from light 
SDS 10% 10% (w/v) Sodium dodecyl sulfate  
Aqua bidest. 
Autoclave 
Sodium phosphate buffer  684 ml 
316 ml 
1 M Na2HPO4 
1 M NaH2PO4 
pH 7.2 
Stripping solution for WB 62.5 mM 
0.1 M 
2% 
Tris/HCl pH 6.8 
β-mercaptoethanol  
SDS 
5 x TBE 445 mM 
445 mM 
10 mM 
Tris/HCl pH 8.0 
Boric acid 
EDTA 
TE buffer 
 
10 mM 
1 mM 
Tris/HCl (stock 1M pH 8.0) 
EDTA 
Aqua bidest. 
10x TE buffer 100 mM 
10 mM 
Tris/HCl (stock 1M pH 8.0) 
EDTA 
pH 8.0 or 7.5 (for Y2H experiments) 
1x TBS 10 mM 
150 mM  
Tris/HCl pH 8.0 
NaCl 
1x TBST washing buffer 1X 
0.1% 
TBS 
Tween®20 
Transfer buffer(1 l) 25 mM 
1.44%(w/v) 
20% 
Tris Base 
Glycin 
Methanol 
Aqua bidest. 
72% Trichloroacetic acid (TCA) 72 g 
100 ml 
Trichloroacetic acid (TCA) 
Aqua bidest 
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10x Tris-Glycine electrophoresis 
buffer 
250 mM 
2.5 M 
1% 
Tris 
Glycine 
SDS 
10x TE buffer 100 mM 
10 mM  
Tris, bring to pH 7.5 with HCl  
EDTA  
d2H20 
1x TE /1x LiAc 0.2 ml 
0.2 ml 
1.6 ml 
10X TE 
LiAc solution 
d2H2O 
   
Tfb 1  30 mM 
50 mM 
100 mM 
10 mM 
15% 
KAc 
MgCl2 
KCl 
CaCl2 
Glycerol 
adjust to pH 5.8 (with 0.2 M NaOH), filter sterilize, 
aliquot and store at -20°C 
 
Tfb 2 10 mM 
75 mM 
10 mM 
15% 
MOPS 
CaCl2 
KCl 
Glycerol 
adjust to pH 6.8 (with acetic acid), filter sterile, 
aliquot and store at -20°C 
1x Thermal buffer (PCR) 20 mM  
10 mM 
10 mM 
2 mM 
0.1% 
(pH 8.8) 
Tris-HCl 
(NH4)2SO4 
KCl 
MgSO4 
Triton X-100 
 
Trypan blue solution 
 
0.9% 
0.5% 
NaCl 
Trypan blue dye 
Aqua bidest. 
2 Material and Methods 
 20 
2.1.6 Culture media 
2.1.6.1 Culture medium for bacteria 
The components for the Luria Bertani (LB) medium were dissolved in d2H2O and 
thereafter the medium was autoclaved 
LB medium 1% peptone 
 0.5% yeast extract 
 1% NaCl 
 1.5% agar (for LB agar plates only) 
 
To select transformed cells, ampicillin or kanamycin was added to the medium to a final 
concentration of 50 µg/ml or 25 µg/ml, respectively. LB-agar medium with antibiotics 
was poured into Petri dishes and stored at 4˚C. 
2.1.6.2 Culture medium for yeast 
All yeast media and solutions were prepared and handled in sterile conditions. 
YPD medium 20 g/l peptone 
 10 g/l yeast extract 
 20 g/l agar (for YPD agar plates only) 
 950 ml d2H2O, autoclave 
The pH was adjusted to 6.5 (with NaOH) and the medium was autoclaved. When medium 
cooled to approximately 55°C, 50 ml of 40% glucose stock solution was added to 950 ml 
of medium. The YPD-agar medium was poured into Petri dishes and stored at 4°C. 
To make minimal yeast medium lacking one or more specific nutrients, a combination of 
minimal SD base and a dropout (DO) solution was used. For each selective SD/DO 
medium, nutrients were added separately according to the desired selection. 10x stock 
dropout solution was prepared lacking histidine, adenine, leucine, or tryptophan (-H/-A/- 
L/-W). 
10x DO -His, -Ade, -Leu,  
-Trp 
 
200 mg 
 
Arginine 
 300 mg Isoleucine 
 300 mg Lysine 
 200 mg Methionine 
 500 mg Phenylalanine 
 2000 mg Threonine 
 300 mg Tyrosine 
 200 mg Uracil 
 1500 mg Valine 
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 1000 ml  d2H2O, autoclave 
SD -His, -Ade, -Leu,  
-Trp 
 
6.7 g 
 
yeast nitrogen base without amino acids 
 20 g agar (for SD plates only) 
 850 ml d2H2O 
 100 ml 10x dropout solution (-His, -Ade, -Leu, -Trp) 
For SD –His, -Leu, -Trp 200 mg Adenine was added 
For SD –Leu, -Trp  200 mg Adenine, and Histidine were added 
The pH was adjusted to 5.8, and the medium was autoclaved. When the medium had 
cooled to approximately 55°C, 50 ml of 40% glucose stock solution was added to 950 ml 
of medium. For SD -His, -Ade, -Leu, -Trp plates supplemented with X-α-gal, 1:1000 
volume of X-α-gal (20 mg/ml in DMF- dimethylformamide) was added to the medium. 
SD-agar medium was poured into Petri dishes and subsequently stored at 4˚C. 
2.1.6.3 Culture medium for cells 
Cell culture media and solutions were handled in sterile conditions and were stored at 
4°C. All cell lines used were cultivated in an incubator set at 37˚C with 95% relative air 
humidity in the presence of 5% CO2. The cell culture media RPMI-1640 and DMEM 
were supplemented with 20% and 10% FBS, respectively. 5 U/ml each of penicillin and 
streptomycin were added. 
2.1.7 Bacterial strain (Escherichia coli) 
Strain Usage 
XL1’ Blue host for plasmid amplification 
XL 10 host of choice for GST fusion protein expression and plasmid amplification  
DH5α host for plasmid amplification 
2.1.8 Yeast strain 
Yeast reporter strain was purchased from DB Biosciences Clontech, Heidelberg, 
Germany 
 
Strain Reporter Transformation markers 
AH 109 HIS3, ADE2, lacZ, MEL1 trp1, leu2 
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2.1.9 Mammalian cell lines 
All cell lines are available from the Cell Culture Collection of the Deutsche Sammlung 
von Mikroorganismen und Zellkulturen GmbH (DSMZ). 
2.1.9.1 Murine and rat cell lines  
 
Name Cell type/ Origin 
NIH3T3 swiss mouse embryo fibroblast 
TGR rat fibroblast 
BA/F3 mouse pro B-cells, IL-3 dependent line established from peripheral blood 
2.1.9.2 Human cell lines 
Normal cell lines 
Name Cell type/ Origin 
293T human embryonal kidney 
LCL 3.1* B-cell EBV mortalized 
*courtesy of Dr. Martin Dreyling, CCG-Leukemia, Grosshadern, Munich 
 
Tumor cell lines 
Name Cell type/ Origin 
HeLa human cervix carcinoma 
U2OS human osteogenic sarcoma, p53 wild type  
SaOS human osteogenic sarcoma, p53 null 
 
B-cell leukemia and B-cell lymphoma cell lines 
Name Cell type/ Origin 
DG-75 Cell line established from the pleural effusion of a 10-year-old boy with Burkitt lymphoma  in 
1975 
Granta 519* Cell line established from the peripheral blood from a 58-year-old Caucasian woman with 
previous history of cervical carcinoma 
 at relapse of a high-grade B-NHL (leukemic transformation of mantle cell lymphoma, stage IV)  
HBL-2* human mature B-cell line derived from B-NHL (diffuse large cell), carries the t(11;14)(q13;q32) 
which juxtaposes the IGH promoter to the BCL1 gene 
JeKo-1* human B-cell lymphoma established from the peripheral blood of a 78-year-old woman with B-
cell non-Hodgkin’s lymphoma (B-NHL), specifically mantle cell lymphoma 
Karpas 422* human B-cell lymphoma established from the pleural effusion of a 73-year-old woman with B-
NHL 
NCEB-1* human mature B-cell line derived from B-NHL (diffuse centroblastic-centrocytic), carries the 
t(11;14)(q13;q32) which juxtaposes the IGH promoter to the BCL1 gene 
Rec* Human B-cell lymphoma, established from the lymph node or peripheral blood from a 61-year-
old man with B-cell Non-Hodgkin lymphoma.  
* courtesy of Dr. Martin Dreyling, CCG-Leukemia, Grosshadern, Munich 
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T-cell leukemia  
Name Cell type/ Origin 
Jurkat* human T cell leukemia, immature T cell line established from the peripheral blood of a 14-year-
old boy with ALL  
HUT78 human mature T-cell line derived from the peripheral blood of a 50-year-old male patient with 
Sézary syndrome (cutaneous T-cell lymphoma).  
MOLT-4 human immature T cell line established from the peripheral blood of a 19-year-old man with ALL 
* courtesy of Dr. Martin Dreyling, CCG-Leukemia, Grosshadern, Munich 
 
Myeloid leukemia cell lines 
Name Cell type/ Origin 
HL-60* human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman 
with AML (FAB M2). Cells can carry amplified c-myc gene and lack wild type p53 
KASUMI-1 
♣ 
human acute myeloid leukemia. Cell line established from the peripheral blood of a 7-year-old 
Japanese boy with AML (FAB M2). Cells carry the t(8;21) ETO-AML1 fusion gene 
K-562 ♣ Human chronic myeloid leukemia in blast crisis, established from the pleural effusion of a 53-
year old woman with chronic myeloid leukemia (CML) Expresses BCR-ABL fusion gene 
MOLM-13 ♣ Human acute myeloid leukemia, established from the peripheral blood of a 20-year-old man with 
AML (FAB M5a) 
U937 human histiocytic lymphoma. Cells express markers and properties of monocytes and carry the 
t(10;11) resulting in the CALM-AF10 fusion gene 
* courtesy of Dr. Martin Dreyling, CCG-Leukemia, Grosshadern, Munich 
♣courtesy of Dr. Tobias Kohl, CCG-Leukemia, Grosshadern, Munich 
 
2.1.10 Plasmids  
pACT2 Shuttle vector for expression of GAL4-AD (amino acids 768-881) fusion 
proteins in yeast, DB Biosciences Clontech, Heidelberg, Germany 
pcDNA6/V5  Contains V5 epitope,  Invitrogen, Karlsruhe, Germany 
pGEM®-T  Cloning vector with 3’-T overhangs at insertion site for direct cloning of PCR 
products, Promega, Madison, USA 
pGEM®-T Easy Cloning vector with 3’-T overhangs at insertion site for direct cloning of PCR 
products, Promega, Madison, USA 
pGBKT7 Shuttle vector for expression of GAL4-DBD (amino acids 1-147) fusion 
proteins in yeast, DB Biosciences Clontech, Heidelberg, Germany 
pGADGH; pGADT7 Shuttle vector for expression of GAL4-AD (amino acids 768-881) fusion 
proteins in yeast, DB Biosciences Clontech, Heidelberg, Germany  
pEYFP-C1 Mammalian expression vector for yellow (YFP) fluorescent fusion proteins, 
DB Biosciences Clontech, Heidelberg, Germany 
pGEX-4T1 Expression of GST fusion proteins in bacterial cells. Vector contains a tac 
promoter for protein expression after IPTG induction, Amersham Pharmacia 
Biotech 
pM1 Mammalian expression vector for  GAL4-DBD (1-147) fusion proteins, DB 
Biosciences Clontech, Heidelberg, Germany 
pGAL4-LUC Reporter plasmid encoding the luciferase gene under the transcriptional 
control of 5 GAL4-binding sites and the min SV40 promoter  
pGAL45tkLUC Reporter plasmid encoding the luciferase gene under the transcriptional 
control of the Herpes simplex virus thymidine kinase promoter and 5 GAL4-
binding sites, (Netzer C. et al., 2001) 
pRL-null Co-reporter vector encoding the Renilla luciferase protein, Promega, 
Madison, USA 
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2.1.11 Constructs 
pcDNA3-FLAG-FHL2  
(aa 1-279) 
Dr. Paul Riley, Molecular Medicine Unit Institute of Child Health, London, 
UK 
pCMX-GAL4DBD-Flirt1    
(aa 1-279) 
Dr. Judith Müller, Universität-Frauenklinik, Freiburg,  Germany 
pGBKT7-CALMΔ10 (aa 1-408) Britta Kaltwasser, CCG Leukemia, GSF, Munich, Germany  
pGBKT7-LIM ½        (aa 1-75)  Zlatana Pasalic, CCG Leukemia,GSF, Munich, Germany 
pGBKT7-LIM ½-1     (aa 1-143)  Zlatana Pasalic, CCG Leukemia,GSF, Munich, Germany 
pGBKT7-LIM ½-2     (aa 1-202)  Zlatana Pasalic, CCG Leukemia,GSF, Munich, Germany 
pGBKT7-LIM ½-3     (aa  1-262)  Zlatana Pasalic, CCG Leukemia,GSF, Munich, Germany 
pGEX-4T-1-FHL2      (aa 1-279) Dr. Judith Müller, Universität-Frauenklinik, Freiburg,  Germany 
GAL4-CALMΔ3  (aa  1-652) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pAS2-CALMΔ1   (aa  1-294) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pAS2-CALMΔ4   (aa  1-335) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pAS2-CALMΔ7   (aa  1-221) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pAS2-CALMΔ8   (aa  1-105) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pEYFP-FHL2       (aa 1-279) Zlatana Pasalic, CCG Leukemia,GSF, Munich, Germany 
YFP-CALM/AF10 Dr. Alexandre Krause, CCG Leukemia, GSF, Munich, Germany 
2.1.12 Oligonucleotides 
All nucleotides were synthesized by Metabion GmbH, Martinsried, Munich, and supplied 
at a concentration of 100 pmol/µl. 
FHL2 specific primers 
Oligonucleotide Sequence Position at  
FHL2 
sequence* 
Tm 
°C 
DRAL66T 5’-GCTGAGAACTGTGTCTTCCTGGAG-3’ 66 61 
DRAL450B 5’-GCATTCCTGGCACTTGGATGAG-3’ 450 61 
FHL2-T-143-BamHI 5’-CATTGGATCCACCATGACTGAGCG 
CTTTGA C-3’ 
143 60 
FHL2-B-961EcoRI 5’-TGTGTTGAATTCGATGTCTTTCCC 
ACAGTC-3’ 
961 60 
FHL2T-XhoI  5’-CCTCTCGAGAAATGACTGAGCGCTTTG-3’ 140 57 
FHL2B-EcoRI 5’-GTGTTGAATTCAGATGTCTTTCCC-3’ 980 57 
FHL2-T94 5’-ATTACCATGGATGGCTGGCATTTT 
GACTTTGGG-3’ 
94 63 
FHL2-LIM1/2 5’-CGGGATCCCTGACGAACAGGGTCT 
CAAAGCACAC-3’ 
226 63 
FHL2-LIM1/2-1 5’-CGGGATCCCGCATTCCTGGCACTT  
GGATGAG-3’ 
429 63 
FHL2-LIM1/2-2 5’-CGGGATCCCTGACGCACTGCATGG  
CATGTTG-3’ 
607 63 
FHL2-LIM1/2-3 5’-CGGGATCCCTGACCCAGCACACTT 
CTTGGCATAC-3’ 
786 63 
*GenBank acc. Nr L42176 (HUMDRAL) 
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Vector primers 
Oligonucleotide Sequence Position Tm °C 
GAPDHforward 5’-GCACCACCAACTGCTTAGCACC-3’ Exon 7  
(530-551) 
60 
GAPDHreverse 5’-GTCTGAGTGTGGCAGGGACTC-3’ Exon 9  
(1166-1146) 
60 
NG2T7/T1096 5’-TGGCAAGCACTGGTCTAT-3; 1073-1091  
Y2H2 5’-TCATCGGAAGAGAGTAG-3’ (1155-1171 pGBKT7) 55 
Y2H3’AD 5’-AGATGGTGCACGATGCACAG 
-3’ 
(2102-2083 pGADT7) 55 
pGEX5’ 5’-GGGCTGGCAAGCCACGTTT 
GGTG-3’ 
(869-891) 55 
pEGFPC-1240-1258 5’-AAAGACCCCAACGAGAAGC-3’ (1240-1258) 55 
*GenBank acc. Nr.: U55763 (pEGFP-C1), U13854 (pGEX-4T2), NM_002046 (human GAPDH) 
2.1.13 Antibodies 
Name Company dilution 
Alexa Fluor® 555 goat anti-mouse Invitrogen 1:500 
Anti-β-Actin clone AC-15 Sigma® 1:2000 
Anti-FLAG Sigma® 1:6000 
Anti-FHL2 (F4B2-B11) Cell Sciences , Inc 1:250 
Anti-GFP rabbit IgG fraction Molecular Probes, Inc. 1:6000 
Anti-V5  Invitrogen 1:6000 
CALM (S-19) Santa Cruz Biotechnology, Inc. 1:1000 
CALM (G-17) Santa Cruz Biotechnology, Inc. 1:1000 
CALM (C-18) Santa Cruz Biotechnology, Inc. 1:1000 
GAL4 (DBD) (RK5C1) Santa Cruz Biotechnology, Inc. 1:1000 
Donkey anti-rabbit IgG-HRP conjugated Santa Cruz Biotechnology, Inc. 1:2000 
Donkey anti-goat IgG-HRP conjugated Santa Cruz Biotechnology, Inc. 1:2000 
goat anti-mouse IgG-HRP conjugated Chemicon International 1:1000-3000 
Goat anti-mouse IgG + IgM-Cy™3 
conjugated 
Jackson ImmunoResearch Laboratories, Inc. 1:500 
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2.2 Methods 
The molecular biology methods in this work were performed according to the “Molecular 
Cloning” (Sambrook and Russell, 2001) with minor or no modifications. All buffers used 
in this work are described in chapter 2.1.5 with exception for some Qiagen and Promega 
buffers.  
2.2.1 Isolation of DNA 
Plasmids were prepared from E.coli XL-1’ blue, DH5α and XL10 bacterial cultures 
grown in the presence of selective antibiotics. All Mini, Midi, Maxi and Mega 
preparations are procedures that isolate plasmid DNA from bacteria, using the alkaline 
method followed by isopropanol precipitation. 
2.2.1.1 Mini preparation (Mini Prep) 
Miniprep were performed during the cloning procedure to isolate small amounts of DNA 
from a large number of clones. Each single colony was inoculated in 4 ml of LB medium 
(plus 100 μg/ml Amp or 50 μg/ml Kan) and grown O/N at 37°C with vigorous shaking 
(260 rpm). 1.5 ml of the overnight culture was transferred to Eppendorf tubes and 
bacterial cells were harvested by centrifugation at 14000 rpm for 2 min. The pellet was 
resuspended in 300 μl of cold buffer P1 containing RNase (0.1 mg/ml). 300 μl of buffer 
P2 was added, mixed gently, and the mixture was incubated at RT for 5 min. The lysed 
pellet was neutralized by gently mixing with 300 μl of Buffer P3, which was immediately 
thereafter centrifuged at 14’000 rpm for 15 min. 800 μl of the supernatant was transferred 
to a new sterile Eppendorf tube and 0.7 volume of isopropanol was added. The precipitate 
was vortexed and incubated at -20°C for 10-20 min and then centrifuged at 14’000 rpm 
for 20 min. The pellet was washed with 500 μl of 70% ethanol and centrifuged 10 min at 
14’000 rpm. Then the pellet was dried for 10-20 min and redissolved in 20 μl of sterile 
water. The DNA was stored at -20°C. 
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2.2.1.2  Midi preparation (Midiprep) 
To isolate larger amount of plasmid DNA for cloning, Midi preparation was done. A  
bacterial colony or 20 μl of a glycerol stock was inoculated in 25 ml of LB medium 
containing appropriate selective antibiotics and grown overnight at 37°C with vigorous 
shaking (270 rpm). Cells were harvested by centrifugation at 6000 x g for 15 min at 4°C. 
4 ml of buffer P1 was used to resuspend the pellet. For cell lysis 4 ml of Buffer P2 was 
added and mixed by inversion, and the mixture was incubated at RT for 5 min. 4 ml of 
pre-chilled Buffer P3 was added, mixed and incubated on ice for 15 min. After incubation 
the mixture was centrifuged at ≥20'000 x g for 30 min at 4°C. The supernatant was 
transferred to fresh 50 ml Falcon tube and once more centrifuged at ≥20'000 x g for 15 
min at 4°C. During centrifugation the Qiagen tip 100 was equilibrated with 4 ml of 
Buffer QBT. The supernatant was then applied to the column, whereafter the flow-
through was discarded and the column-bound DNA was washed twice with Buffer QC. 
The DNA was eluted with 5 ml of Buffer QF and precipitated with 0.7 volumes RT 
isopropanol (in order to minimize the salt precipitation). The mixture was mixed and 
centrifuged at ≥15'000 x g for 30 min at 4°C. The supernatant was carefully discarded 
and the pellet was washed with 2 ml of RT 70% ethanol by centrifugation at ≥15'000 x g 
for 10 min at 4°C. Ethanol removes the precipitated salt and replaces isopropanol with 
the more volatile ethanol. The pellet was air dried for 5-10 min and redissolved in 100 μl 
or appropriate volume of 1x TE buffer or sterile d2H2O. To ensure that the DNA plasmid 
obtained was correct a digestion with appropriate restriction enzymes was performed. 
2.2.1.3 MaxiEndofree preparation (Maxi Prep) 
For transfection experiments the DNA was prepared using Qiagen Maxi Endofree kit. A 
bacterial colony or 20 μl of a glycerol stock were inoculated in 100 ml of LB medium in 
the presence of ampicillin (50 μg/ml) or kanamycin (25 μg/ml), and grown overnight at 
37°C with vigorous shaking (230 rpm). The cells were harvested by centrifugation at 
6000 x g for 15 min at 4°C. 10 ml of buffer P1 was used to resuspend the pellet. For cell 
lysis 10 ml of Buffer P2 was added and mixed by inversion, and the mixture was 
incubated at RT for 5 min. The solution was neutralized by adding 10 ml of ice-cold 
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buffer P3 and gently inversion. The suspension was applied into the Qiafilter Cartridge 
and incubated at RT for 10 min. Thereafter the suspension was filtered through the 
Qiafilter Cartridge. 2.5 ml of ER buffer was added to the lysate and the solution was 
incubated at ice for 30 min. During the incubation a Qiagen column was equilibrated with 
10 ml Buffer QBT. The supernatant from the cell lysate was subsequently poured into the 
column to bind the DNA to the column. The DNA was eluted with 15 ml of Buffer QN 
and precipitated with 0.7 volumes of isopropanol by centrifuging ≥ 15’000 x g for 30 min 
at 4°C. To neutralize the isopropanol the DNA pellet was washed with 15 ml of 70% 
ethanol by centrifuging ≥ 15’000 x g for 15 min at 4°C. The supernatant was discarded 
and the pellet was dried for 10-20 min and dissolved in 200-500 μl, depending of the size 
of the pellet, of endotoxin Free buffer (EB). After determining the concentration the 
DNA was stored at -20°C. To ensure that the DNA plasmid obtained is correct a 
restriction enzyme digestion analyses is done. 
2.2.1.4 Mega Preparation (Mega Prep) 
After amplifying the yeast two hybrid thymus cDNA library as single colonies on 150 
mm LB plates a plasmid mega preparation was performed. The colonies from the plates 
(50 plates) were scraped into 500 ml LB medium with selective antibiotics, and grown at 
37˚C O/N with vigorous shaking (300 rpm). The overnight culture was harvested by 
centrifuging at 6000 x g for 15 min at 4˚C. The pellet was resuspended in 50 ml buffer 
E1. For cell lysis 50 ml E2 was added and mixed until a homogenous lysate was 
obtained. Neutralization of lysis was performed by mixing 50 ml E3. The mixture was 
centrifuged for 20 min at 12’000 x g at RT, meanwhile the MEGA Cartridge was 
equilibrated with 100 ml buffer E4. The suspension was filtered through the MEGA-
cartridge and the DNA absorbed to the column. DNA was eluted with 50 ml of elution 
Buffer E6 and precipitated with 0.7 volumes of isopropanol by centrifuging ≥ 13’000 x g 
for at least 30 min at 4°C. The precipitated DNA was washed with 10 ml of 70-80% 
ethanol by centrifugation for 5 min at 13’000 x g at 4°C. Pellet was air dried for 10 min 
at RT and then redissolved in appropriate volume of 1xTE. The DNA was stored at -20°. 
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2.2.2 Determination of nucleic acid concentration  
To determine the quality and yield, the DNA was measured with an UV 
spectrophotometer (BioPhotometer 6131, Eppendorf) at a wavelength of 260 and 280 nm. 
The dilution used for measurements was 1:100. DNA preparations with a concentration 
of less than 0.2 μg/ml and a ratio below 1.5 were discarded. The DNA concentration is 
calculated by the spectrophotometric conversion in which 1A260 unit corresponds to 50 
μg/ml of double-stranded DNA or 40 μg/ml of RNA (Sambrook, 1989).  
2.2.3 Digestion of DNA 
Type II restriction endonucleases are essential for specific digestion of DNA. These 
enzymes recognize, bind and cleave short defined mostly palindromic base sequences in 
the DNA. Different buffers are used for different enzymes, but for multiple enzyme 
digestion the Five Buffer Plus System such as Y+/Tango™ (MBI Fermentas), was 
required. The digest with a single restriction enzyme was performed in an Eppendorf tube 
as follows: 
1 μg  DNA 
5U restriction enzyme 
1-2X  appropriate restriction enzyme buffer  
x μl,  up to 20 μl, of sterile water  
The reaction was incubated from 2-3 h to O/N at 37°C (or at the recommended 
temperature) depending on enzymes used. 
2.2.4 Ethanol precipitation of DNA 
Ethanol precipitation was used to purify DNA from buffers in previous reactions (e.g. 
digestion and sequencing). 1 volume of DNA sample was mixed with 2.5 volumes of 
100% - ethanol and 1:10 volumes of 3M NaAc (pH 5.2). The mixture was incubated at -
20°C for 10 min and centrifuged at 14 000 rpm in a table top centrifuge for 30 min at 
4˚C. The supernatant was discarded and the pellet was washed with 500 μl of 70% 
ethanol by centrifuging at top speed for 10 min at 4°C. The pellet was dried at RT or for 
10 min at 56˚C in a thermo block. The pellet was resuspended in 20μl 1x TE or sterile 
d2H2O. The purified DNA was stored at -20˚C. 
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2.2.5 Ligation 
Both the vector and the insert (the restriction fragment) were restricted in such a way that 
they contained compatible ends. A 1:4 (vector: insert) ratio was used and mixed in a 1.5 
ml eppendorf tube as described below: 
X ng  restricted vector DNA (2.2.3) and  
X ng  insert purified (2.2.4) 
4 μl  5X T4 DNA ligase buffer 
1 μl  T4 DNA ligase (5 U/μl) 
to 20μl  d2H2O 
The ligation reaction was incubated O/N at 4 ˚C. 
2.2.6 DNA transformation into bacterial cell 
For bacterial transformation two different protocols were used, the heat shock and the 
electroporation transformation. For chemical transformation the XL10 cells were used 
while the electrocompetent Epicurian coli XL1-blue cells were used for the 
electroporation. The buffers used are described in 2.1.5. 
2.2.6.1 Preparation of chemically competent cells 
An aliquot (200 μl) of frozen cells (E. coli strain XL10) was inoculated into 10 ml LB 
medium and incubated O/N with vigorous shaking at 37°C. The O/N culture was diluted 
in 300 ml LB medium and incubated for an additional 2-3 hrs until the culture reached an 
OD600 of 0.5-0.7. The bacterial culture was cooled on ice and cells were harvested by 
centrifugation at 4000 rpm at 4°C. The cell pellet was resuspended in 100 ml Tfb1 and 
incubated on ice for 10-15 min. The suspension was centrifuged at 4 000 rpm at 4°C for 
10 min, whereafter the supernatant was discarded and the cells were resuspended in 4 ml 
of Tfb2. The competent cells were aliquoted (200 μl), frozen in liquid nitrogen and stored 
at -80°C.  
2.2.6.2 Transformation 
100 μl of the chemically competent cells were mixed with 1 to 5 µl of 50-100 ng/μl 
plasmid DNA or 5μl ligation reaction (2.2.5). The reaction was first incubated on ice for 
30 min then heat shocked for 50 sec at 42°C and then again cooled on ice for one more 
minute. 900 μl LB medium was added to the reaction, which was incubated for 1h 
2 Material and Methods 
 31 
shaking at 37°C. After incubation, cells were streaked on LB agar plate with appropriate 
selective antibiotics. The plates were then incubated O/N at 37°C. 
2.2.6.3 Preparation of XL1-Blue electrocompetent cells 
An aliquot (50μl) of frozen cells (E. coli strain XL1-blue MRF’) was inoculated into 10 
ml LB medium and incubated O/N with vigorous shaking at 37°C. The overnight culture 
was diluted in 400 ml LB medium and incubated for 2-3 hrs until the culture reached an 
OD600 of 0.5-0.6, and was then cooled on ice. The cells were harvested by centrifugation 
and the pellet was washed twice with 40 ml ice cold sterile d2H2O, twice with 20 ml ice 
cold 10% glycerol (in d2H2O) and then resuspended in 800 μl 10% glycerol. The 
electrocompetent cells were aliquoted in 50 μl and stored at -80°C. The centrifugation 
steps were all carried out at 4 500 rpm for 5 min at 4°C. 
2.2.6.4 Electroporation 
Electrocompetent cells (50 μl aliquot) (2.2.6.3) were mixed with 1 μl plasmid DNA (50-
100 ng) or 1 μl ligation reaction (2.2.5). They were thereafter incubated for 1 min on ice 
and transferred to a pre-cooled electroporation cuvette. The cuvette was placed in an 
electroporator and cells were electroporated at 2.5 kV in 3-4 msec pulse (Easyject-
Equibio, 6.125 kV/cm maximum field strength). 1 ml of pre-warmed LB medium (37°C) 
was immediately added to the cells and the suspension was transferred to a fresh 
Eppendorf tube. The cells were incubated for 1 h vigorously shaking at 37°C, then plated 
on LB agar plates containing selective antibiotics, and incubated O/N at 37°C. 
2.2.7 Agarose-gel electrophoresis for DNA 
To separate DNA fragments both for analysis and isolation, non denaturing agarose gel 
electrophoresis was used. According to the size of the linear DNA fragments to be 
separated, gels of different concentration were used.  
Agarose (%)  Range of separation of linear DNA 
0.5   700 bp to 25 kbp 
0.8   500 bp to 15 kbp 
1.0   250 bp to 12 kbp 
1.2   150 bp to 6 kbp 
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Agarose was mixed and boiled in 50 ml 0.5x TBE. 3 μl Ethidium bromide was added to 
the solution and the gel was poured into a gel chamber. The DNA samples were mixed 
with 1x Blue Juice loading buffer (2.1.5) and then loaded in the wells. The negatively 
charged nucleic acids were run under electric current (60-110 V) moving from the 
negative to the positive pole. 
2.2.8 Isolation of DNA fragments  
After the gel electrophoresis the DNA fragments were cut out of the gel under the UV 
light (312 nm) and transferred to an Eppendorf tube. The Qiagen Gel Extraction Kit 
(using microcentrifuge) was used to extract the DNA from the agarose gels. For each 100 
mg gel slice 300 μl buffer QG was added and the reaction was incubated at 50°C for 10 
min. Every 2-3 min the tubes were vortexed. When the gel slice had dissolved 
completely, 1 gel volume of the isopropanol was added and mixed. To bind the DNA, 
800 μl of the reaction was applied to a QIAquick column and centrifuged for one minute. 
Flow-through was discarded and the column was soaked with 750 μl wash Buffer PE for 
3 min and thereafter the bound DNA was washed by centrifugation for one minute. The 
flow-through was discarded and the QIAquick column was centrifuged for additional one 
minute to remove the residual ethanol from the buffer. The QIAquick column was 
transferred to a fresh sterile microcentrifuge tube and the DNA was eluted with 30 μl 
elution buffer EB or sterile d2H2O by centrifugation for one minute. The DNA was stored 
in -20°C. The purified DNA fragments were used for reactions such as ligations (2.2.5).  
2.2.9 RNA extraction 
2.2.9.1 RNeasy® Mini Kit  
Total RNA was prepared from cultured cell lines (2.2.13) with the RNeasy® Mini Kit 
(Qiagen). For RNA extraction, approximately 5.5 x 106 cells were lysed by the addition 
of 600 μl RLT buffer. For homogenization, samples were applied to a QIAshredder spin 
column placed in a 2 ml collection tube and centrifuged for 2 min at 14’000 rpm at 20-
25˚C. 1 volume (600 μl) of 70% ethanol was added to the homogenized lysate and mixed 
thoroughly by pipetting. 700 μl of the lysate was applied to a RNeasy mini column placed 
in a 2 ml collection tube and centrifuged for 15 sec at 8 000 x g. The flow-through was 
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discarded and the RNA bound to the column was washed once with 700 μl RW1 buffer 
(15 sec at 8 000 x g) and twice with 500 μl RPE buffer (2 min at 8 000 x g). The flow-
through was discarded after each washing step. RNeasy column was placed in a fresh 1.5 
ml tube. To elute the RNA that was bound to the column 50 μl RNase-free H2O was 
applied to the column and incubated for 1 min at RT. The RNA was collected By 
centrifuging for one minute at 8000 x g. The RNA concentration was measured as 
described in (2.2.2), and the quality was determined by loading 2 μl of the prepared RNA 
on a 1% agarose gel (2.2.10). The RNA was stored at -80°C. 
2.2.9.2 Trizol RNA extraction 
For total RNA extraction approximately 5.5 x 106 cells were harvested by centrifugation 
at 1000 x g for 5 min at 4˚C. The cells were lysed in 1 ml TRIzol Reagent by repetitive 
pipetting and then incubated at RT for 5 min. 0.2 ml chloroform per sample was added 
and shaked vigorously by hand for approximately 15 sec and then incubated at RT for 2-3 
min. The phase separation was performed by centrifugation at 12’000 x g for 15 min at 
4˚C. The mixture separated in lower red, phenol-chloroform phase, an interphase and a 
colorless upper aqueous phase, which contains the RNA. The aqueous phase was 
transferred to a fresh RNAse free tube and 0.5 ml of isopropanol was added. The samples 
were incubated for 10 min at RT and centrifuged at 12 000 x g for 10 min at 4˚C and 
RNA precipitate formed a gel like pellet. The supernatant was discarded and 1 ml of 75% 
ethanol was added to the RNA pellet, vortexed and centrifuged at 7’500 x g for 5 min at 
4˚C. RNA pellet was air dried for 10 min at RT or 1 min at 58°C and dissolved in an 
appropriate volume, 50-75 μl, of DEPC-H2O. The samples were incubated at 58°C for 10 
min. RNA aliquots were stored in -80°C.  
2.2.10 Agarose-gel electrophoresis for RNA 
To analyze the quality of the RNA, a denaturing 1%- agarose gel was prepared by boiling 
1g of Agarose in 74 ml DEPC-H2O and 10 ml 10x MOPS RNA running buffer. When the 
gel was cooled down 16.6 ml of 37% formaldehyde was added. Gel solution was poured 
into an RNase free gel chamber and the RNA samples were prepared on ice to avoid 
degradation. 1 μl of the RNA sample was mixed with 5μl DEPC-H2O, 5 μl 1.5x RNA 
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sample buffer and 1 μl EtBr (1 μg/ μl). The RNA samples were then incubated at 65°C 
for 10 min and then cooled on ice for one minute. 3 μl of RNA loading buffer was added 
to the mixture and the samples were run on the gel. The electrophoresis was carried out in 
1x MOPS running buffer (diluted in DEPC- H2O) at RT for 1,5 hr at 60V. 
2.2.11 cDNA synthesis – reverse transcriptase reaction 
cDNA is DNA synthesized in vitro on a RNA template by the reverse transcriptase 
enzyme. The most important advantage of cDNA is that it is more stable than mRNA and 
can be used as template in PCR reactions. A complementary DNA strand -cDNA, of 
mRNA is synthesized with the extension of oligo(dT) primers by the reverse transcriptase 
enzyme. cDNA is used as a template for subsequent PCR reactions as described in 2.2.12. 
To avoid genomic DNA contamination the RNA (2.2.9) was pretreated with DNAse I as 
follows: 1 μg of RNA was mixed with 1 μl 10x DNase I reaction buffer, 1 μl DNase I (1 
U/μl) and DEPC- H2O to a final volume of 10 μl and then the mixture was incubated for 
15 min at RT. The reaction was inactivated by adding 1 μl of 25 mM EDTA and heating 
it at 65ºC for 10 min. For the cDNA synthesis 2 μg DNAse-free RNA was mixed with 5 
μl dNTP mix (2 mM), 1 μl oligo(dT) primer (500 μg/ml) and DEPC- H2O to a final 
volume of 12 μl. The mixture was denatured at 65ºC for 5 min and then chilled on ice for 
1 min. The contents of the tube was collected by brief (5-10 sec) centrifugation and 4 μl 
of 5x First-Strand Buffer, 2 μl of 0.1M DTT and 1 μl RNaseOut recombinant 
ribonuclease inhibitor (40 U/μl) were added to the reaction. The mixture was gently 
mixed and incubated at 42ºC for 2 min. 1 μl of SuperScript II enzyme was added to the 
reaction and the mixture was incubated at 42°C for 50 min. The RT enzymes was 
nactivated incubating the reaction at 70ºC for 15 min. For the PCR reactions (2.2.11) 1 μl 
of the synthesized cDNA (20 μl total vol.) was used. 
2.2.12 Polymerase chain reaction- PCR 
The PCR technique is employed to amplify specific regions of DNA in vitro. This is 
achieved by using two primers (synthetic DNA oligonucleotides) flanking the sequence 
to be amplified. The principle of the PCR is that the reaction needs a brief heat treatment 
to separate the two strands of the DNA double helix. Subsequent cooling of the reaction 
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and an excess of the two primers DNA oligonucleotides allows the primers to hybridize 
to the target sequence. The annealed mixture is then incubated with DNA polymerase and 
dNTPs so that the region downstream of the primers is synthesized. When the procedure 
is repeated the newly synthesized fragments serve as template, and already after few 
cycles there is an excess of the desired DNA fragment because it is amplified in an 
exponential fashion. As the template 1 μl cDNA (2.2.11), or 0.5 ng plasmid DNA was 
used. The PCR reaction was performed by mixing template, 2 μl 10x PCR Buffer, 1.5-
5mM total concentration of MgCl2 depending on the primer pairs, 2 μl dNTP (2 mM), 0.2 
μM- 0.5 μM forward primer (tot. conc.), 0.2 μM- 0.5 μM reverse primer (tot. conc.), 0.16 
μl Taq polymerase (5 U/μl) and d2H2O to a final volume of 20 μl. Sometimes reactions 
were scaled up to a volume of 50 μl. 
Reaction was run in a thermocycler as follows: 
95°C : 2 min    (denaturation) 
94°C : 30- 45 sec   (denaturation),  
56°C-62°C: 30 sec to 1 min  (annealing),  
72°C : 40-45 sec   (extension) (25-35 cycles) 
72°C : 5 min    (final extension) 
Depending on the primer pair, the annealing temperature varied. The extension time 
varied according to the expected size of the PCR product. As a general rule of thumb 1 
min per kb was used. 
2.2.12.1 DNA Sequencing 
DNA Sequencing was performed to identify a clone or to examine the fidelity of plasmid 
DNA after a cloning step. The sequencing reactions were performed according to the 
Sanger chain-termination method. Cycle-sequencing, like ordinary PCR, consists of 
cycles of denaturation, annealing and extension in presence of polymerase and dNTP’s, 
with the exception that by sequencing additional dye labeled ddNTP’s are also added.  
Reaction was prepared as follows:  
4 μl BigDye terminator   
1 μl primer (1 μM tot.conc)  
1 μg DNA was used of plasmid DNA, 
4 μl d2H2O 
To 10 μl total volume of per reaction.  
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Reaction was run in a thermocycler as follows: 
96°C: 2 min  (denaturation), 
96°C: 30 sec   (denaturation),  
50°C: 15 sec  (annealing),  
60°C: 4 min  (extension)  
(25 cycles) 
After cycling had been completed, 10 μl d2H2O was added to the reaction followed by 
ethanol precipitation (2.2.4). The precipitated DNA was diluted in 20 μl sterile d2H2O 
whereafter 10μl was used to run the samples into the Genetic Analyzer automated 
sequencer ABI PRISM 310 (PE Applied Biosystems). 
 
2.2.13 Cloning of constructs 
For mapping the CALM interaction domain of FHL2 in the yeast two hybrid system, 
various portions of the FHL2 cDNA were inserted into the pGBKT7 vector to produce a 
series of GAL4 DBD-FHL2 deletion mutants. The appropriate portions of the FHL2 
cDNA were amplified with the primers FHL2-T, FHL2-LIM1/2, FHL2-LIM1/2-1, FHL2-
LIM1/2-2 and FHL2-LIM1/2-3 (2.1.12) and inserted into the NcoI and BamHI restriction 
sites of the pGBKT7 vector (fig 3.4 A).  
For immunofluoroscence, the pEYFP-FHL2 construct was cloned. The full length FHL2 
DNA fragment was generated by PCR amplification using pACT2-FHL2 with primers 
containing sites for the restriction enzymes XhoI and EcoRI (FHL2T-XhoI and FHL2B-
EcoRI). The 840 bp PCR product corresponding to FHL2 isoform 2 was digested with 
these restriction enzymes and cloned in frame with the green fluorescent proteins into the 
pEYFP-C1 vector (2.1.10).   
For immunoprecipitation, the pcDNA6/V5-FHL2 construct was cloned. The full length 
FHL2 DNA fragment was generated by PCR amplification using pACT2-FHL2 with 
primers containing sites for the restriction enzymes BamHI and EcoRI (FHL2-T-143-
BamHI and FHL2-B-961EcoRI. The 818 bp PCR product corresponding to FHL2 
isoform 2 was digested with these restriction enzymes and cloned in frame with the V5 
proteins into the pcDNA6/V5 vector (2.1.10).   
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2.2.14 Culture of mammalian cells 
Adherent cells were grown in DMEM supplemented with 10% heat inactivated FBS and 
1% penicillin/streptomycin. Suspension cells were grown in RPMI medium 
supplemented with 20% heat inactivated FBS. Cells were cultured in a humidified 
incubator with 5% carbon dioxide at 37°C. Splitting of confluent cultures of adherent 
cells was done every 2-4 days in a 1:4- 1:6 ratios. The cells were first washed with DPBS 
and then trypsinized with Trypsin/EDTA for approximately 5 min at 37°C. Fresh medium 
was added to the trypsinized cells, whereafter the cells were replated in new Petri dishes. 
Suspension cells were split by aliquoting part of the growing culture in a new flask and 
then adding fresh medium to these cells. For long-term storage, the cells were harvested 
by centrifuging for 5 min at 1 000 rpm at 4°C. The pellet was then washed with DPBS 
and resuspended in 90% FBS and 10% DMSO. The cells were aliquoted in Cryotube™ 
vials and were put in pre cooled ice box that was then placed in a -80°C freezer.  
2.2.15 Transient transfection of adherent cells 
For protein co-localization and protein expression, transient transfections were 
performed, using Roti®-Fect and polyethylenimine (PEI) transfection reagents. For co 
localization, one day before transfection, approximately 4x105, cells were seeded and 
grown in 6-well plates, with 18x24 mm cover slips placed in the wells. 2 ml of growth 
medium was added and the cells were incubated O/N (or until the cells were 30-40% 
confluent).  
For reporter gene assay, 5x104, HEK 293T cells were seeded the day before transfection 
and grown in 24 well plates with 0.5 ml of growth medium containing serum. The cells 
were incubated O/N. The transfection was performed on the next day. To examine the 
functional role of the CALM on GAL4 DBD-FHL2 the total amount of 1020 ng DNA 
was transfected into, 5x104cells; 400 ng of plasmid encoding GAL4 SV40 minimal 
promoter, 20 ng of p-RL co reporter vector (Promega), 200 ng GAL4 DBD-FHL2 and 
100, 200 respectively 400 ng YFP-CALM.  
To investigate the role of CALM/AF10 on GAL4 DBD-FHL2, the total amount of 1020 
ng DNA was transfected; 400 ng of plasmid encoding SV40 minimal promoter, 20 ng of 
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p-RL co reporter vector (Promega), 200 ng GAL4 DBD-FHL2 plasmid and 100, 200 or 
400 ng YFP-CALM/AF10 plasmid.  
To study the role of FHL2 on GAL4 DBD-CALM/AF10, cells were co transfected with 
100 ng plasmid encoding GAL4 SV40 minimal promoter, 10 ng of p-RL co reporter 
vector (Promega), 100 ng GAL4 DBD alone or GAL4 DBD-CALM/AF10 expression 
plasmids and 100 ng FLAG-FHL2. The total amount of the transfected DNA was kept 
constant by adding pcDNA6/V5 in all experiments. 
For the protein extractions, 2x106 cells were seeded in a 100 mm Petri dish the day before 
the transfection. On the next day, the cells were washed with DPBS and 8 ml fresh 
medium was added.  
For reporter gene assay-the different DNA concentrations described, for co localization- 
2 μg plasmid DNA and for the protein extraction 8 μg plasmid DNA was mixed with 30, 
60 or 200 μl pure medium (free from serum and antibiotics) in reaction A. In reaction B -
30, 60 or 200 μl medium and 10-50 μl Roti®-Fect or 1.5 volumes of PEI was mixed. In 
order to form DNA lipid complexes reaction A and B were mixed and incubated for 30 
min. The cells were meanwhile washed with DPBS and growth medium with serum was 
added to the cells. The mixture of the DNA lipid complex was added to the cells and 
incubated for 24-48 hrs. After incubation, the cells were either harvested for reporter 
gene assay (2.2.23) and protein extraction (2.2.17) or fixed for microscopy (2.2.15).  
2.2.16 Fixation of transfected cells and microscopy 
After the transfection (2.2.14), cells were once washed with ice cold PBS and fixed for 10 
min in RT with freshly prepared 2% paraformaldehyde (in PBS). After fixation, the cells 
were washed with ice cold PBS and stained with 2 ml DAPI solution (5 mg/ml stock 
diluted 1:10’000 in PBS) for 2 min. The cells were washed one more time with PBS 
whereafter the coverslips were mounted on glass slides with Dakocytomation Mounting 
Medium and sealed with nail polisher. The Axiovert 200M microscope (Carl Zeiss, Jena, 
Germany), with filter sets for visualization of DAPI, cyan (CFP) and yellow (YFP) and 
Texas Red was used to observe the cells. Openlab 3.08 software (Improvision, Coventry, 
UK) was used to record the images of the cells. 
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2.2.17 Yeast two hybrid 
The yeast two hybrid assay is a sensitive method for detecting weak and transient protein 
interactions in living yeast cells. Even though some interactions cannot be biochemically 
detectable they may be critical for proper functioning of complex biological systems, 
(Van Criekinge W. and Beyaert R., 1999). The yeast two hybrid assay is a GAL4-based 
assay, based on the coexpression of the bait protein (here CALM fused in frame to the 
GAL4- DBD) and a prey protein (a library of random cDNA’s expressing protein X fused 
in frame to the GAL4-AD). The plasmid cDNA library used for the screen was a 
commercially available HeLa cDNA-library that was cloned into the pGAD-GH vector 
and a human thymus cDNA library cloned into pACT2. When an interaction between the 
bait and prey proteins occurs, the GAL4-DBD and GAL4-AD are brought into proximity 
and a transcriptional activator complex is reconstituted that activates the expression of 
reporter genes in the yeast (Figure 2.1). The yeast strain used is AH109 that contains the 
reporter constructs in which the ADE2, HIS3 and lacZ/MEL1 genes are under control of 
different GAL UAS and TATA boxes. The single yeast clones can be obtained by plating 
them on selective plates. Expression of HIS3 and ADE2 enables the yeast cells to grow 
on plates lacking nutrients (2.1.6.2). MEL1 provides the catalytic color reaction on the 
plates supplemented with X-α-GAL. The product of MEL1 gene converts  X-α-GAL into 
a blue color.  
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Figure 2.1The CALMΔ10 fused to GAL4 DBD binds to GAL4-UAS upstream of the reporter genes. 
If no interaction occurs with a protein fused to AD the transcription of the reporter genes is not activated. If 
the interaction appears the transcription of the reporter genes will be activated. 
The LiAc- transformation method is a method of introducing foreign DNA into the yeast. 
Typically it has a transformation efficiency of 105 transformants per μg of DNA when a 
single type of plasmid is used. If the yeast is simultaneously co-transformed with two 
plasmids, the efficiency is usually an order of magnitude lower due to the lower 
probability that a yeast cell will take up both plasmids. The lithium acetate method is 
based on the fact that the competence of DNA uptake level of the cell wall is induced by 
treatment with lithium ions and PEG. 
The day before the experiment a pre-culture was prepared with 50 ml of YPD with 2% 
glucose inoculated with a fresh (< 1 month old) AH109 yeast colony. Thereafter it was 
vortexed vigorously for 5 min to disperse any clumps. The pre-culture was incubated at 
30˚C overnight shaking at 250 rpm. The OD600 was measured until it had reached 1.5. 30 
ml of the overnight culture was diluted into 300 ml of YPD or to an OD600 of 0.2-0.3. The 
incubation of the diluted culture is continued for 3 hrs and the OD600 is again measured. It 
should have a value of 0.4-0.6 when the yeast is in its log-phase growth. Cells are 
harvested at that moment by centrifuging them at 1000 x g for 5 min at RT. The cell 
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pellet is resuspended in 25 ml of sterile water and recentrifuged at 1000 x g for 5 min at 
RT. Then the cells are resuspended in sterile 1xTE/ 1xLiAc. For each transformation 
reaction, 100 μl of competent yeast cells, 0.1 mg herring testes carrier DNA and 0.1 μg 
plasmid DNA were mixed in a sterile 1.5 ml eppendorf tube, and 600 μl of 1x PEG/LiAc 
solution was added. The transformation reaction was incubated at 30˚C, vigorously 
shaking at 200 rpm for 30 min. Then 70 μl of DMSO was added and the culture was 
mixed gently by inversion, followed by a heat shock at 42˚C for 15 min. The cells were 
cooled on ice for 1-2 min and then centrifuged in RT at top speed for 5 sec. The pellet 
was resuspended in 1xTE buffer. 100 μl of the cells were streaked on selective plates and 
incubated at 30˚C until the colonies appeared (3-7 days). 
2.2.17.1 Test of the bait protein 
Using the lithium acetate transformation protocol, pGBKT7-CALMΔ10 and pGBKT7 
(used as the control) were transformed separately into the yeast strain AH109. The cells 
were streaked on SD –Trp plates. The transformed yeast cells were then replated on 
plates lacking Trp and His. If growth occurred on this selection plate, it would indicate an 
activation of the HIS3 reporter gene through the bait protein alone. This would mean that 
the construct would have to be modified to exclude any domain that acts as an activation 
domain. 
2.2.17.2 Large scale cDNA library transformation 
To obtain high transformation efficiency e.g. high number of transformants expressing 
individual library plasmids, a large scale transformation was done with the Hela S3 and 
the human thymus cDNA libraries. By sequential transformation the pGBKT7-
CALMΔ10 bait plasmid was introduced into the yeast cells as in small scale 
transformation described in 2.2.16.1. The pGBKT7-CALMΔ10 positive colonies were 
grown on SD –Trp plates whereafter they were made competent as described in 2.2.16.1. 
16 μl (8µg)  of Thymus cDNA and 2 μl (3µg) of HeLa cDNA was used to obtain a 
maximal amount of transformation efficiency (this was calculated in pilot experiments), 
that in this case was 4x104 transformants/μg DNA. After the transformation cells were 
incubated in 12.5 ml (250 μl/plate) of YPD medium for 1hr in 30°C. After centrifuging, 
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the pellet was washed and resuspended in 12.5 ml 1xTE buffer. 250 μl of the transformed 
yeast cells were plated on 50 medium stringency (SD –Trp, -Leu, -His) selection plates, 
which were incubated at 30°C for 3 to 7 days or until the colonies appeared. To estimate 
the transformation efficiency, 2 μl of the transformation mixture was streaked on SD –
Leu and SD –Trp, -Leu. 
2.2.17.3 Isolation of plasmid DNA from yeast 
The positive clones were inoculated into 2 ml of SD-medium in a sterile 15 ml Falcon 
tube, and grown O/N at 30°C with vigorous shaking (230rpm). 1.5 ml of each overnight 
culture was transferred to an Eppendorf tube and was spun for 5 sec at top speed. The 
pellet was vortexed and thereafter resuspended in 200 μl of breaking buffer, 0.3 g of glass 
beads (0.45-0.52 mm acid-washed) and 200 μl of phenol/chloroform/isoamyl (25:24:1). 
This mixture was vortexed for 2 min at high speed, and thereafter centrifuged for 5 min at 
top speed at RT. 250 μl of the supernatant was then transferred to a new Eppendorf tube, 
and the DNA was ethanol precipitated as described in 2.2.4. The DNA was resuspended 
in 20 μl sterile water and 5 μl were used for transformation into chemically competent 
bacterial cells 2.2.6.1. 
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2.2.18 Protein extraction 
2.2.18.1 Protein extraction from yeast cells 
A fresh (< 1 month old) yeast colony was inoculated in 5 ml YPD medium, mixed by 
vortexing and incubated O/N at 30°C with vigorous shaking (230 rpm). The overnight 
culture was measured with UV-spectrometer as described in chapter 2.2.2 and a total 
volume of 2 OD’s were transferred to fresh Eppendorf tubes. The culture was centrifuged 
for 15 min at 14’000 rpm at RT. The pellet was resuspended in 250 μl of 50 mM Tris (pH 
8). 50 μl of Rödel mix (2.1.5) was added to the mixture and incubated for 10 min on ice. 
220 μl of 72% Trichloroacetic acid (TCA) was added and the mixture was mixed by 
vortexing. Another incubation was done on ice for 15 min, whereafter the mixture was 
centrifuged for 40 min at 14 000 rpm in 4ºC. The pellet was washed with 1ml pre cooled 
acetone by centrifuging 10 min at 14 000 rpm at 4ºC. Pellet was air dried for 10 min at 
RT, and resuspended in 200 μl of 2x Lämmli buffer. Samples were subsequently boiled 
for 5 min at 95ºC, and 30 μl of the samples were loaded on a 10% SDS PAGE.  
2.2.18.2 Protein extraction from mammalian cells 
Extraction of proteins from transfected and non-transfected cells was performed by 
washing the cells with ice-cold PBS (2000 rpm for 5 min at 4˚C). The cells were lysed in 
RIPA buffer (for Western blot), with freshly added protease inhibitors (cocktail diluted 
1:100). The cells were homogenized by rotating them (15 rpm) at 4ºC for 30 min and 
thereafter the cell extract was cleared by centrifugation at top speed for 15 min at 4ºC. 
The supernatant was transferred to a fresh sterile microcentrifuge tube and stored at -
80ºC. 
2.2.18.3 Cytoplasmic protein extraction for immunoprecipitation (IP) 
1x107 293T cells were harvested by centrifuging at 1 000 rpm for 5 min. The cells were 
washed three times with 5 ml ice cold PBS by centrifuging at 2 000 rpm for 5 min. The 
pellet was resuspended in buffer A (2.1.5) and incubated on ice for 10-15 min with 
occasional tapping. Nuclei were pelleted by centrifugation at 2 000 rpm for 5 min at 4°C. 
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The cytoplasmic fraction (the supernatant) was transferred to a fresh sterile 
microcentrifuge tube and was further used for IP (2.2.21).  
2.2.19 Determination of protein concentration 
The Bradford method was used to determine of protein concentration. A standard Bovine 
Serum Albumine- BSA curve, against which the protein concentration was measured, 
was calibrated with diluted stock solution (1 μg/μl BSA) in the volume of d2H2O shown 
in the table below. 
BSA 0 1 5 10 15 20 25 
d2H2O 800 799 795 790 785 780 775 
Bradford 
reagent 200 200 200 200 200 200 200 
 
For measuring the protein, 1 μl of the protein extract was diluted in 799 μl d2H2O and 
200 μl of Bradford reagent was added to each sample. Measurements were performed 
with an Eppendorf BioPhotometer 6131. 
2.2.20 SDS-PAGE gel electrophoresis 
The protein samples prepared for the analyses were all denatured and coated with 
detergents by heating in the presence of SDS and a reducing agent. This results in a net 
negative charge which is proportional to the size of the protein. The proteins are then 
separated on the basis of their molecular mass. To separate the proteins, SDS-
Polyacrylamide (SDS-PAGE) gel electrophoresis with denaturing conditions was used. 
Depending on the size of the proteins, the concentration of the gels was determined 
according to the table below: 
Linear range of separation (kDa)   Acrylamide concentration (%) 
12-43     15 
16-68     10 
36-94     7.5 
57-212    5 
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The components for the resolving gel were mixed as follows: 
Components (5 ml)  8%  10%  12% 
d2H2O   2.3 ml  1.9 ml 1.6 ml 
30% Acrylamide mix 1.3 ml  1.7 ml  2.0 ml 
1.5 M Tris/HCl (pH 8.8)  1.3 ml  1.3 ml  1.3 ml 
10% SDS   0.050 ml  0.050 ml  0.050 ml 
10% APS   0.050 ml 0.050 ml 0.050 ml 
TEMED   0.003 ml  0.002 ml 0.002 ml 
The stacking gel was prepared after the resolving gel was polymerized as follows: 
Components (2 ml)   Stacking gel 5% 
d2H2O   1.4 ml 
30% Acrylamide mix   0.33 ml 
1 M Tris/HCl (pH 6.8)   0.25 ml 
10% SDS    0.02 ml 
10% APS    0.02 ml 
TEMED    0.002 ml 
As the resolving gel already was polymerized the stacking gel was poured directly on it. 
2.2.20.1 Coomassie staining  
To detect the proteins in the gel after the electrophoresis, the PAGE gel was Coomassie 
stained by incubating the gel for 1 h in Coomassie® solution (BioRad) at RT with gentle 
shaking. The proteins were fixed and the unspecific binding of the Coomassie® solution 
was washed away with 10% acetic acid and 40% methanol diluted in d2H2O. Destaining 
was performed at RT O/N, or until the protein bands were visible. The stained gel was 
fixed by incubation in 1% glycerol diluted in d2H2O for 30 min to 1 hour with gentle 
shaking at RT. Finally, the gel was dried for 2 hrs at 80˚C in a Gel Air™ Drying System 
(BioRad). 
2.2.20.2 Western blot analysis 
After separation on a SDS PAGE gel, the proteins were transferred to membranes for 
further analysis. The transfer from the SDS PAGE gel to a nitrocellulose membrane was 
performed with a semi-dry system. The blotting papers (GB003) and the nitrocellulose 
membrane were pre-wetted in transfer buffer. 3 sheets of blotting paper, the nitrocellulose 
membrane, the gel and finally again the 3 blotting papers were laid on top of each other 
on a Trans-Blot® SD Semi–Dry Transfer Cell (BioRad). The negatively charged proteins 
were transferred to the membrane under electric current from negative to the positive 
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pole at 200 mA for 1 hr. After transfer, the non specific binding sites on the membrane 
were blocked with 5% nonfat dried milk for one hour at RT. The specific antibodies were 
diluted in 5% nonfat dried milk to their optimal concentration. Immunoblotting was 
carried out by incubating the primary antibodies O/N at 4˚C. Then the membranes were 
washed 3x10 min with TBST, to remove all the unbound antibodies. To detect the 
primary antibody, a secondary antibody1 was applied to the membrane and incubated for 
1 hr at RT whereafter the membrane was washed (3x10 min) with TBST. Finally, 
enhanced chemiluminescent reagent was applied for 5 min at RT (ECL, Amersham 
Pharmacia biotech). The membrane is then wrapped in Saran wrap and placed in an X-
ray cassette. The films were exposed between 15 sec and 15 min depending on the 
strength of the signals.  
Re use of the membranes was possible by stripping, which was performed by incubating 
membranes in the stripping solution (2.1.5) at 56˚C for 1hr. The stripped membrane was 
washed twice with TBST for 10 min and the blocking procedure with milk was repeated 
as described above.  
2.2.21 Expression of GST fusion proteins 
To express the GST-FHL2 fusion protein the bacterial strain XL1’blue (2.1.7) was 
transformed (2.2.6.3), with the pGEX4T1-FHL2 construct (2.1.11). The transformed 
colonies were inoculated into 10 ml LB medium with Ampicillin and inoculated O/N at 
37°C with vigorous shaking. The O/N culture was diluted in 100 ml LB medium with 
Ampicillin and grown to an OD600 of 0.6-0.8 at 37°C. The expression of the GST fusion 
protein was induced by incubating the cells for 2 hrs in the presence of 1 mM IPTG. The 
cells were harvested by centrifugation at 4 500 rpm for 15 min at 4°C and the pellet was 
resuspended in 5 ml ice-cold NETN buffer plus protease inhibitors (1:100 protease 
inhibitor cocktail and 1 mM PMSF). Sonification of the cells was performed for 30 sec 
on ice, whereafter the cell lysates were transferred to Eppendorf tubes and centrifuged at 
14 000 rpm for 5 min at 4°C. The protein extracts were stored at -80°C. To examine if the 
                                                 
1 The secondary antibody, conjugated to horseradish peroxidase (HRP) enzyme catalyzes a colorimetric reaction when 
appropriate reagent is added, here ECL (Amersham Pharmacia biotech), resulting in a deposition of the substrate on the 
membrane at the reaction site. 
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induction of proteins had occurred, 20 μl of the lysates were run on a SDS PAGE gel 
whereafter the gel was Coomassie stained (2.1.5). 
2.2.21.1 Purification of GST fusion proteins 
The GST fusion proteins were purified by incubating them with 100 μl Glutathione-
agarose beads (pre washed 3x in NETN buffer) O/N at 4˚C with 15 rpm rotation. The 
beads were pelleted by centrifugation at 1000 x g for 5 min at 4˚C, and subsequently 
washed 3 times with ice cold NETN buffer. 10 μl of the slurry beads in buffer were ran 
on SDS PAGE gel and stained with Comassie solution (2.2.19.1).  
2.2.21.2 In-vitro-expression of the radiolabeled protein 
The in vitro expression system, TNT® -reticulocyte-lysate system from Promega was 
used to label proteins with radioactive S35-methionine. The proteins to be expressed were 
cloned in-frame into the pGBKT7 vector (2.1.10). This vector contains a T7 promoter 
sequence at the 5’ end of the multiple cloning sites. T7 RNA polymerase is used to 
transcribe the insert at high copy number in the reticulocyte lysate and the resulting RNA 
is then translated into proteins. The Master Mix contains the reticulocyte lysate, RNA 
polymerase, amino acids excluding the methionine, RNasin ribonuclease inhibitors and 
buffer. 
The procedure was performed as follows: 
40 μl of TNT Master Mix   
2 μl   of [S35] Methionin (>1.000Ci/mmol at 10mCi/ml, Amersham) 
1 μl   of DNA Template(s) (1 μg/μl) 
7 μl   Nuclease-Free Water  
The reaction was incubated at 30°C for 90 min. 
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2.2.21.3 In vitro GST pulldown assay 
The purified GST fusion protein (2.2.20.2) was used for the GST pulldown assay. The 
reaction for the pulldown was mixed as follows:  
20   μl of in vitro translated (S35-methionine-labeled) pGBKT7-CALMΔ10 
10   μl of  purifed GST-FHL2 
100 μl GST-buffer 
The reaction was incubated ON at 4˚C on a rotating platform. After incubation the 
reaction was centrifuged for 5 min at 2000 rpm at 4˚C. The beads were washed 4 times 
with 500 μl GST buffer (2.1.5) and finally resuspended in 20 μl of 2x Lämmli loading 
buffer (2.1.5). The reaction was boiled at 95°C for 5 min and run on 10% SDS PAGE gel. 
The gel was stained with Comassie blue for 1h and thereafter destained with a solution 
consisting of 10% acetic acid and 90% d2H2O. To avoid damage to the gel during drying, 
the gel was incubated in 1% glycerol water for 30 min. The gel was placed onto pre-
wetted 3 MM Whatman paper, covered with Saran wrap and dried at 80°C under constant 
vacuum for 2 hrs. The Saran wrap was then removed, and the gel was exposed to an X-
ray film (Kodak) O/N at RT. 
2.2.22 Immunoprecipitation 
Plasmids expressing the desired proteins were co transfected into HEK293T cells by the 
lipofectamin method (2.2.14) Cells were lysed as described in 2.2.17.3 24 h after the 
transfection. Protein G-agarose beads (Roche) were washed with DPBS. 200 μl lysate 
was incubated with 3μg anti-CALM antibodies (2.1.13) for 1 hr. Thereafter the protein 
G-agarose beads were added to the total lysate and the mixture was incubated for another 
3 hrs rotating in 4˚C and then put on ice for 30 min. The mixture was centrifuged for 5 
min at 2000 rpm at 4˚C. The supernatant was discarded and the beads were washed with 
1 ml NETN buffer (2.1.5) 4 times. The beads were resuspended in 5 μl of Lämmli buffer 
and boiled at 95 ˚C for 5 min. The immunoprecipitated proteins were analyzed by 10% 
SDS-PAGE (2.2.19), blotted, and detected with, respectively, monoclonal mouse anti-V5 
and a mixture of polyclonal goat anti-CALM antibodies. Secondary antibodies used were 
the horseradish peroxidase-coupled goat anti-mouse and the donkey anti-goat IgG. 
Detection was achieved with the ECL detection system (2.1.1). 
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For the second immunoprecipitation experiment performed with GFP binder beads 
(Rothbauer U. et al., 2008)200 µl lysate as described in 2.2.17.3, 15µl slurry pre washed 
GFP binder beads, and 200 µl IP buffer (2.1.5) were incubated for 30 min rotating at 4ºC. 
The beads were then washed 3x with the IP buffer whereafter they were resuspended in 5 
μl of Lämmli buffer and boiled at 95 ˚C for 5 min. 
2.2.23 Immunofluoroscence 
2x 105 U2OS cells were seeded and grown on 18 x 24 mm coverslips placed in 6 well 
plates. Cells were incubated for 24 hrs at 37°C in a CO2 incubator. Thereafter they were 
washed with PBS and fixed for 10 min in 2% PFA (2.1.5). After fixation, the cells were 
washed 3x with PBS and incubated in the dark for 15 min in PBS/NP-40 (0.1%) 
whereafter the cells were blocked with PBS/FBS (10%) for 1.5 hour in RT. For the 
immunofluoroscence reaction the FLAG antibodies were diluted 1:500 in 1.5 ml 
PBS/FBS (1.5%), added to the fixed cells  and incubated O/N at 4°C in a humidified 
chamber. Next step was to wash the cells 3x6 min with PBS/NP-40 (0.1%) at RT. The 
secondary antibody Alexa 555 diluted 1:500 in PBS/FBS (1.5%) and the cells were 
incubated for 45 min at RT. The cells were subsequently washed 3x15 min with PBS/NP-
40 (0.1%). Finally a DAPI counter-stain (5 mg/ml stock solution, diluted 1:10’000 in 
PBS) was applied for 2 min and the cells were washed once with PBS. Coverslips were 
mounted on slides with Dakocytomation Mounting Medium and sealed with nail polish. 
Cells were visualized with an automated Axiovert 200M microscope (Carl Zeiss, Jena, 
Germany) equipped with single-band pass filter sets for visualization of DAPI, yellow 
(YFP) and red (Cy3) fluorescence.  
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2.2.24 GAL4-based reporter gene assays 
Reporter gene assays are used to study eukaryotic gene expression. They are most 
frequently used as indicators for the transcriptional activity in the cells. The reporter 
system used is based on the expression of a protein of interest fused to GAL4-DNA 
binding domain (DBD) in the mammalian system. The protein is targeted to the cell 
nucleus and bound to the GAL4UAS that is located in the promoter region of the reporter 
gene. If the protein of interest has transcriptional properties it will either repress or 
activate the expression of the luciferase reporter genes as seen in fig 2.2.  
 
Figure 2.2 Reporter gene assay. In mammalian cells the GAL4-DBD fusion protein is expressed. The 
GAL4-DBD of the fusion protein binds to the GAL4UAS in the promoter region of the reporter gene. (A) If 
the expressed protein is an activator of transcription the transcription of the luciferase reporter gene, from 
the pGAL4LUC plasmid, will be induced. (B) If the protein is a repressor of transcription the constitutive 
expression of the luciferase reporter gene, from the pGAL45tkLUC plasmid will be repressed.  
Transfection of the human embryonal kidney 293T cells was performed as described in 
2.2.16. 24 hrs after the transfection, cells were washed with 1 ml PBS and 120 μl of 
passive lyses buffer (PLB) was added to the cells (5x104 cells). The cells were incubated 
for 15 min at RT shaking vigorously. After incubation, the cell lysates were mixed by 
pipetting and 10 μl of the lysate was applied to 96-well luminometry plates (Promega). 
The Dual-Luciferase® Reporter Assay System (Promega) was used because it provides 
the possibility to measure the two reporter genes firefly Photinus pyralis and Renilla 
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Renilla reniformis, sequentially from a single sample. The assay was processed by Orion 
Microplate Luminometer as follows: 50 μl Luciferase Assay Reagent II (LARII) was 
injected to the samples and the firefly luciferase activity was measured. Next, Stop & 
Glo® Reagent was injected to the samples and the Renilla luciferase activity was 
measured. The program was performing a 2-sec pre measurement delay, followed by a 
10-sec measurement period for each reporter assay. Firefly luciferase expression was 
normalized to the Renilla luciferase expresssion. 
2.3 Micro array analysis 
2.3.1 Expression analysis of FHL2 in leukemia samples 
Micro array data from 139 samples, 129 leukemia samples and 10 normal bone marrow 
samples, were used to analyze the expression levels of FHL2. The HG-U133A and HG-
U133B Affymetrix chips were used. The leukemic patient samples were from 13 
different leukemia subgroups; CML, CALM/AF10 positive leukemias, AML_nk: AML 
with normal karyotype, AML_comp: AML with complex aberrant karyotype, 
AML_MLL: AML with MLL rearrangement,s AML_M4: AML with CBFB/MYH11 
fusion, AML_M3: AML with PML/RARA fusion, AML_M2: AML with AML1/ETO 
fusion, AML_FLT3: AML with normal karyotype and with a FLT3 internal tandem 
duplication, ALL_Ph: ALL with BCR/ABL fusion, c-ALL (common ALL) and pro-ALL. 
The data set was normalized using the VSN (Variance stabilization and calibration for 
microarray data) and presented as boxes using the “boxplot” function. The expression 
signal intensities are displayed on a logarithmic scale.  
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3 Results 
3.1 Identification of CALM interacting proteins using the yeast two 
hybrid system 
In order to identify CALM-interacting proteins, yeast two-hybrid screens were 
performed. Previously, different CALM deletion mutants had been cloned in frame into 
the pGBKT7 and pAS2 yeast expression vectors as fusions with the GAL4 DNA binding 
domain (GAL4-DBD). They had been tested for transcriptional activity in yeast with 
respect to different reporter genes (HIS3, ADE2 beta-GAL) (2.2.16.2). These 
experiments revealed the presence of at least two independent transcriptional 
transactivation domains in CALM between aa 408 and 572. The longest C-terminal 
CALM deletion mutant without transactivation activity, the pGBKT7-CALMΔ10 (fig 
3.1), was used as bait for the yeast two hybrid screens (Fröhlich-Archangelo L. et al., 
2006)  
 
Figure 3.1 Diagrammatic representation of GAL4-DBD-CALM deletion constructs. “+” and “-“ 
indicates growth and no growth of AH109 yeast cells transformed with the CALM deletion constructs and 
then plated on SD plates lacking tryptophan and histidine (Fröhlich-Archangelo L. et al., 2006). 
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Two human cDNA libraries expressing proteins as GAL4 activation domain fusion 
proteins (prey) were screened with the pGBKT7-CALMΔ10 bait plasmid: a HeLa (HeLa 
S3) and a Thymus cDNA library.  
If the bait and prey proteins interact the GAL4-DBD and GAL4-AD are brought into 
proximity. The transcriptional activator complex is then reconstituted and activates the 
expression of reporter genes in the yeast. The yeast strain used was AH109 which 
includes four reporter genes ADE2, HIS3 and lacZ/MEL1 genes.  
For the yeast two hybrid screen using the HeLa cDNA library, a high stringency screen of 
2x106 transformants yielded 2 and 3 colonies in two independent screens. These clones 
were able to grow as blue colonies on highly stringent selection plates lacking histidine, 
adenine, leucine and tryptophan (-His, -Ade, -Leu, -Trp) supplemented with X-α-GAL 
(2.2.16). The product of MEL1 reporter gene converts the colorless X-α-GAL substrate 
into blue color. The prey plasmid (pGAD-GH) inserts of these colonies were sequenced 
with vector primers Y2H2 and Y2H3’AD (2.1.12). A BLAST nucleotide similarity 
search of the insert sequences revealed homologies with four genes: 1) CALM interacting 
protein expressed in thymus and spleen (CATS); 2) poly(rC)-binding protein 1 (PCBP1); 
3) Tumor susceptibility gene 101 protein (TSG101), 4) Clathrin assembly lymphoid 
myeloid leukemia protein (CALM). Table 3.1 summarizes the potential interacting 
proteins of CALM from the screens with the HeLa cDNA library and gives a brief 
description of each interaction protein.  
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Table 3.1 Putative CALM interacting partners obtained from the HeLa S3 cDNA library 
Protein 
name 
Sub Cellular 
localization 
Protein description* No of 
independent 
clones 
NCBI 
Accession 
Nummer 
CATS Predominantly in 
nucleus 
CALM interacting protein 
expressed in thymus and spleen 
[1] 
1 NM_019013 
PCBP1 Nucleus. 
Cytoplasm 
poly(rC)-binding protein 1. 
Single-stranded nucleic acid 
binding protein that binds 
preferentially to oligo dC [2] 
1 NM_006196.2 
TSG101 Cytoplasm Tumor susceptibility gene 101 
protein. Regulator of vesicular 
trafficking process. [3] 
1 BC002487 
CALM Cytoplasm Clathrin assembly lymphoid 
myeloid leukemia protein. 
Involved in CALM/AF10 
translocation.  Recruites clathrin 
and adaptor protein complex 2 
(AP2) to cell membranes..[4] 
1 AB210017.1 
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In the thymus cDNA library high stringency screen of a total of 2x106 transformants in 
two screens 4 independent colonies were obtained in the first screen and 3 independent 
clones in the second screen. These 7 clones grew as blue colonies when plated on -His, -
Ade, -Leu, -Trp selection plates supplemented with X-α-GAL. The inserts of the prey 
plasmids (pACT2) from these clones were sequenced, and the BLAST analysis revealed 
homologies to five different cDNAs. For one clone no sequence could be obtained. Two 
clones were coding for Filamin A (FLNA). One clone each was identical to: 1) Fatty acid 
binding protein 4- (FABP4); 2) Poly(rC) binding protein 1 (PCBP1); 3) Dipeptidyl-
peptidase 7 (DPP7); 4) Four and a half LIM domain protein 2 (FHL2). Table 3.2 
summarizes the potential interacting proteins of CALM from the screen with Thymus 
cDNA library and gives a brief description of each interaction-protein.  
Protein 
name 
Sub Cell 
localization 
Protein description* Nr of 
independent 
clones 
NCBI Accession 
Nummer 
FLNA cytoplasmic Filamin A, actin binding protein 
280, promotes orthogonal 
branching of actin filaments and 
links actin filaments to membrane 
glycoproteins [5] 
2 NM_001456 
FABP4 cytoplasmic Fatty acid binding protein 4, 
adipocyte. Lipid transport protein 
in adipocytes. Binds both long 
chain fatty acid and retinoic acid 
[6] 
1 BC003672.1 
PCBP1 Nucleus. 
Cytoplasm 
poly(rC) binding protein 1, 
Single-stranded nucleic acid 
binding protein that binds 
preferentially to oligo dC , [7] 
1 NM_006196.2 
DPP7 Lysosome. 
Cytoplasmic 
vesicle 
dipeptidyl-peptidase 7, Plays an 
important role in the degradation 
of some oligopeptides [8] 
1 NM_013379 
FHL2 Nucleus. 
Cytoplasm 
Four and a half LIM domain 
protein 2. Transcriptional co 
activator of β-catenin, integrin-
signaling pathway.  
1 L42176.1 
 
Table 3.2 Putative CALM interacting partners from the Thymus cDNA library. 
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Figure 3.2 schematically depicts the full length cDNA sequence (protein coding region as 
bigger dark grey box) of the CALM interacting proteins (top in each drawing) and the 
prey clones (bottom) obtained from the library screens. The activation domain (AD) 
encodes for 113 amino acids of the yeast GAL4 transcription factor which is part of the 
prey vector. The pink colored box denotes the sequenced part of the clones. The clones 
were sequenced from the 5’ as well as the 3’ ends using Y2H2 and Y2H3’AD primers 
(2.1.12). From our yeast two hybrid experiment we obtained the C-terminus of the 
alternative spliced variant 2 coding for isoform 2 of CATS. The prey clones of PCBP1, 
CALM, FABP4 and DPP7 do not contain the N terminus. The FHL2 prey clone was full 
length. Note that FLNA is drawn at half scale compared to the other clones.   
3 Results 
 
 57 
   
 
3 Results 
 
 58 
  
 
Figure 3.2 Map of cDNA, Open Reading Frames (ORFs) of full length proteins and the extent of the 
DNA sequence in the prey clones isolated in the yeast two hybrid screens with pGBKT7-CALMΔ10. 
Activation domain (AD) is coding for 113 amino acids. The pink colored box denotes the sequenced part of 
the clones. The clones were sequenced from the 5’ as well as the 3’ ends using Y2H2 and Y2H3’AD 
primers (2.1.12). From our yeast two hybrid experiment we obtained the alternative spliced variant 2 
coding for isoform 2 of CATS. CALM, FABP4 and DPP7 sequences are all missing the N-terminal part, 
however the missing parts are of different sizes. TSG101 and FLNA obtained from the yeast two hybrid are 
containing the C-terminal part of the full length sequence. FHL2 obtained from the yeast two hybrid screen 
3 Results 
 
 59 
is the full length FHL2. Because of the size, FLNA is depicted in half size in comparison to the rest of the 
proteins 
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3.2 Confirmation of potential protein interactions 
As an initial test to confirm that the proteins identified in the screen are indeed CALM 
interacting partners, we co-transformed the CALM bait plasmid with the individual prey 
plasmids into yeast strain AH109. Figure 3.3 shows the growth of the co-transformed 
yeast clones containing the CALM bait and one of the prey plasmids of the interacting 
partners: FHL2, FABP4, PCBP1, DPP7, CALM, TSG101, CATS and FLNA (FLJ00343) 
on selective plates lacking the essential nutrients histidine (His, H), adenine (Ade, A), 
leucine (Leu, L) and tryptophan (Trp, W). These results indicate that all the clones 
initially identified in the screen could be confirmed as potential interacting partners. 
 
Figure 3.3 Interaction of CALM with 8 different proteins. Yeast strain AH109 was cotransformed with 
pGBKT7-CALMΔ10 and the prey plasmids from the screen. Transformed cells were streaked on high 
stringency SD plates lacking His, Ade, Trp and Leu. 
The different interaction partners of CALM suggest that CALM is involved in several 
different cellular processes. The CALM interaction partner FHL2, which had been shown 
to be important in several leukemia-associated cellular pathways, was chosen for further 
detailed analysis including colocalization, co-immunoprecipitation experiments and 
reporter gene assays. 
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3.3 Mapping of the CALM-FHL2 interaction in yeast 
3.3.1 Construct of FHL2 bait protein 
For mapping the CALM interaction domain of FHL2, various portions of the FHL2 
cDNA were inserted into the pGBKT7 vector to produce a series of GAL4 DBD-FHL2 
deletion mutants. The appropriate portions of the FHL2 cDNA were amplified with the 
primers FHL2-T, FHL2-LIM1/2, FHL2-LIM1/2-1, FHL2-LIM1/2-2 and FHL2-LIM1/2-3 
(2.1.12) and inserted into the NcoI and BamHI restriction sites of the pGBKT7 vector (fig 
3.4 A). As a full length FHL2 clone the prey clone (fused to GAL4 AD) obtained from 
the two hybrid screen was used. 
The FHL2 deletion mutants were transformed into yeast strain AH109. The expression of 
the different FHL2 deletion mutants was analyzed with Western blot using a GAL4-DBD 
antibody. Lanes 1- 6 show pGBKT7-LIM1/2, pGBKT7-LIM1, pGBKT7-LIM2, 
pGBKT7-LIM3, pGBKT7-CALMΔ10 and pGBKT7 empty, respectively (fig 3.4 B). The 
full length FHL2 fused to the GAL4-AD (original prey plasmid) was detected with a 
GAL4-AD antibody as seen in lane 1 in fig 3.4 C. 
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Figure 3.4 A) Diagram of the FHL2 deletion constructs cloned into pGBKT7. The deletion constructs 
were cloned into pGBKT7 vector to produce GAL4-DBD-fused FHL2 deletion proteins. The full length 
FHL2 clone in the pACT2 vector was obtained from the initial yeast two hybrid screen. B) Western blot of 
FHL2 deletion mutants fused to the GAL4 DBD. Protein was isolated from AH109 cells transformed 
with pGBKT7-LIM ½ (Lane 1), pGBKT7-LIM ½-1 (lane 2), pGBKT7-LIM ½-2 (lane 3), pGBKT7-LIM 
½-3 (lane 4), pGBKT7-CALMΔ10 (lane 5) and pGBKT7 alone in lane 6. GAL4-DBD antibodies were 
used for detection. C) Western blot of FHL2 fused to the GAL4-AD. pACT2-FHL2 (lane 1) and 
pGBKT7 alone in lane 2 were transformed in AH109 yeast cells. GAL4-AD antibodies were used for 
detection. 
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3.3.2 Mapping of the CALM interaction domain of FHL2 
The different FHL2 deletion mutants had been tested for transcriptional activity with 
respect to different reporter genes in AH109 (HIS3, beta-GAL) (2.2.16.2). These 
experiments did not reveal a transcriptional transactivation domains in FHL2 (data not 
shown). To map the CALM interaction domain of FHL2, pGAD-GH-CALM (aa 114-
652) was cotransformed into AH109 with the deletion mutants of FHL2 (described in 
1.3.1). Note that the full length FHL2 (fused to GAL4-AD obtained from the screen) was 
transformed with pGBKT7-CALMΔ10 (2.1.11). Co transformants were plated on 
selective plates lacking His, Ade, Leu and Trp. Growth occurred only when full length 
FHL2 was co transformed with pGBKT7-CALMΔ10, fig 3.5.  
 
Figure 3.5 Full length FHL2 is needed for the interaction with CALM. The yeast strain AH109 was 
cotransformed with the various pGBKT7-FHL2 deletion mutants and the pGAD-GH-CALM (expressing aa 
114-652) clone or with the pGBKT7-CALMΔ10 (fig 3.1) and the pACT2-FHL2 clone. Transformed cells 
were streaked out on selective plates lacking tryptophan, leucine, histidine and adenine. The interaction 
occurs only between the full length FHL2 fused to GAL4 AD and pGBKT7-CALMΔ10. 
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3.3.3  Mapping the FHL2 interaction domain of CALM 
To map the FHL2 interaction domain on CALM, the various CALM deletion mutants 
fused to the GAL4-DBD (in the pGBKT7 and pAS2 plasmid) and FHL2 fused to GAL4-
AD (in pACT2) shown in fig 3.1, were used in the yeast two hybrid assay. The co-
transformants were assayed for growth on selective plates as seen in fig 3.6. CALMΔ4 
(aa 1-335) and CALMΔ10 (aa 1-408) show an interaction with FHL2 in contrast to 
CALMΔ1 (aa 1-294), CALMΔ7 (aa 1-221) and CALMΔ8 (aa 1-105) which are not 
displaying any interaction. These data suggest that FHL2 requires amino acids 294-335 
of CALM for interaction.  
 
Figure 3.6 FHL2 interacts with amino acids 294 to 335 of CALM. The yeast strain AH109 was 
cotransformed with plasmids expressing GAL4 DBD-CALM deletion mutants and a plasmid (pACT-
FHL2) expressing the GAL4 AD-FHL2 fusion. Transformed cells were serially diluted (1:100, 1:1000, 
1:10000 and 1:20000) and plated on medium lacking histidine, adenine, leucine and tryptophan ( -H/ -A/-
L/-W). The interaction occurs only between the CALM deletion mutants CALMΔ10 and CALMΔ4, and 
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the full length FHL2 indicating that the FHL2 interaction domain in CALM lies between 294 and 335 of 
CALM. 
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3.4 CALM-FHL2 GST pulldown assay 
To confirm the direct interaction between CALM and FHL2, a glutathione S-transferase 
(GST) pulldown assay was carried out. 
3.4.1 Expression of FHL2  
For the GST pulldown assay, full length FHL2 fused to GST expressed from the pGEX-
4T1-FHL2 plasmid was used (2.1.11) (fig 3.7) (Müller J. et al., 2000). Bacterially 
expressed GST-FHL2 protein was purified using glutathione sepharose beads. 
 
Figure 3.7 Diagram of FHL2 fused to GST. The FHL2 was cloned into pGEX-4T1 vector (Müller J. et 
al., 2000). 
Subsequently the samples were loaded on a SDS PAGE gel and stained with Coomassie 
blue, fig 3.8. 10 μl of the proteins were loaded per lane.  
 
Figure 3.8 GST and the GST-FHL2 fusion protein on a Coomassie stained PAGE gel. Lane 1: protein 
expressed from empty pGEX-4T1. Lane 2) GST-FHL2. In each lane 10 µl protein lysate was loaded. The 
total amount of lysate was obtained from a 50 ml culture.  
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3.4.2 CALM interacts with FHL2 in vitro 
To analyze the CALM-FHL2 interaction in vitro, a GST pulldown assay with the full 
length FHL2 fused to GST (GST-FHL2) and a S-35 methionine labeled CALMΔ10 
protein (expressed from pGBKT7 in a TNT reaction) was performed. Only GST-FHL2 
construct bound to glutathione beads was able to retain the S-35 methionine-labeled 
CALM, fig 3.9. Input reflects 10% of the protein incubated with the beads.  
 
Figure 3.9 GST pulldown assay. Lane 1) 10% input of the S35-labeled CALMΔ10 protein. Lane 2) no 
unspecific interaction occurs between GST only and S35-labeled CALMΔ10 protein. Lane 3) Direct 
interaction between full length FHL2 fused to GST and CALMΔ10 proteins is confirmed. 
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3.5 CALM interacts with FHL2 in vivo 
To establish whether CALM and FHL2 interact in vivo, a co-immunoprecipitation 
experiment was performed. Human endothelial kidney (HEK) 293T cells were transiently 
co-transfected (2.2.14) with pEYFP-C1-CALM and pcDNA6/V5-FHL2 (2.1.11). 
Immunoprecipitation was performed using CALM antibodies. After immunoprecipitation 
and Western blotting, the mixture of polyclonal anti-CALM antibodies detected the 
immunoprecipitated YFP-CALM fusion protein and the two bands with the expected size 
of endogenous CALM (66 and 72 kDa), (fig 3.10). The membrane was stripped and 
reprobed with a monoclonal anti-V5 antibody. In lane 2 a band can be seen which 
corresponds to the co-immunoprecipitated V5-FHL2 protein. A weak band is also seen in 
lane 1, suggesting that endogenous CALM interacts with overexpressed V5-FHL2. In 
lanes 4, 5 and 6 the input lysates are run as controls for protein expression. These results 
clearly show that the overexpressed YFP-CALM protein interacts with the overexpressed 
V5-FHL2 protein and that it is very likely that endogenous CALM is also interacting with 
the overexpressed V5-tagged FHL2 protein. 
 
Figure 3.10 CALM interacts with FHL2 in vivo. Lane 1) Precipitation of endogenous CALM with 
CALM antibodies co-precipitates small amounts of the overexpressed V5-FHL2, seen as a weak band. 
Lane 2) Precipitation of YFP-CALM with CALM antibodies co-precipitates V5-FHL2. FHL2 is detected 
with a V5 antibody. Lane 3) V5 alone and the precipitated YFP-CALM detected with CALM antibody. 
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Lanes 4), 5) and 6) loaded with the input lysates. The amounts of heavy chain detected in lane 1, 2 and 3 
demonstrate that the amount of antibodies used in the experiment is constant. 
 
To exclude nonspecific binding between YFP and FHL2 we performed the co-
immunoprecipitation also using the GFP-binder protein, which is a single chain camelid 
antibody highly specific for GFP (Rothbauer U. et al., 2008). While precipitation of YFP-
CALM results in co-precipitation of FLAG-FHL2, precipitation of YFP alone does not 
co-precipitate FLAG-FHL2, (fig 3.11) YFP and YFP-CALM are detected by rabbit 
monoclonal anti GFP antibodies, while FHL2 is detected with the mouse monoclonal 
anti-FLAG antibody.  
 
Figure 3.11 CALM interacts with FHL2 in vivo. The precipitation was performed with GFP-binder 
(Rothbauer U. et al., 2008)  Lane 1) 10% of the input lysate from 293T cells expressing YFP-CALM and 
FLAG FHL2. Lane 2) The precipitated YFP-CALM co-precipitates FLAG-FHL2. Lane 3) 10% of the 
lysate input, from 293T cells expressing YFP and FLAG FHL2. Lane 4) The precipitated YFP does not co-
precipitate FHL2. YFP-CALM is detected with rabbit anti- GFP antibody and FLAG-FHL2 is detected 
with mouse monoclonal anti-FLAG antibody. 
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3.6  Co-localization of CALM and FHL2 
To further explore the CALM-FHL2 interaction and examine whether the expression of 
one of the proteins has an influence on the subcellular localization of the other protein, a 
YFP-tagged CALM and CALM/AF10 protein (YFP-CALM, YFP-CALM/AF10) and a 
FLAG-tagged FHL2 (FLAG-FHL2) were co-expressed in U2OS (Human Osteosarcoma 
cells). The transfected cells were fixed and then stained with FLAG antibody before 
being analyzed with a confocal microscope. As previously reported, YFP-CALM and 
YFP-CALM/AF10 are predominantly located in the cytoplasm (fig 3.12). It has also been 
shown that CALM and CALM/AF10 shuttle between the cytoplasm and nucleus 
(Fröhlich-Archangelo L. et al., 2006). YFP-CALM is rather homogenously distributed in 
the cytoplasm, while the cells expressing YFP-CALM/AF10 have a “speckled” pattern in 
both the cytoplasm and to a lesser extent also in the nucleus. In particular, it was 
noticable that cells expressing YFP-CALM/AF10 are partially forming cytoplasmic 
inclusions in contrast to cells expressing YFP-CALM or YFP-FHL2. As previously 
reported, FHL2 is localized in both the cytoplasm and the nucleus (fig 3.12) (Lee S-W. et 
al., 2005; Ng E.K. et al., 2002). After incubation with FLAG antibodies and Alexa 555 
conjugated secondary antibodies, no signal is detected in the Cy3 channel in cells that 
were only transfected with YFP-CALM, YFP-CALM/AF10 or YFP-FHL2. Only 
minimal background signal is detected in the Cy3 channel at the maximum level of laser 
stimulation (600 V). Thus we exclude cross reactivity between the FLAG antibody and 
YFP-fusion-proteins in the immunofluorescence experiments described below. 
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Figure 3.12 YFP-CALM, YFP-CALM/AF10 and YFP-FHL2 overexpressed in U2OS cells. YFP-
CALM and YFP-CALM/AF10 are mainly located in the cytoplasm. In cells expressing YFP-CALM/AF10, 
inclusion bodies are visualized, in contrast to the cells expressing YFP-CALM and YFP-FHL2. YFP-FHL2 
is located in both nucleus and cytoplasm. Since only minimal background signal is seen in the Cy3 channel 
the cross reaction between the FLAG antibody and the three different YFP-fusion proteins used in co-
localization experiments was excluded.  
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In cells co-expression YFP-CALM and FLAG-FHL2, co-localization of the two proteins 
can be observed in the cytoplasm and also in several nuclear spots. Co-localization is 
indicated by yellow color in the merged image and overlapping peak intensities in the 
line scan (fig 3.13). Thus, shuttling YFP-CALM might be retained in the nucleus through 
interaction with FLAG-FHL2.  
  
Figure 3.13 CALM and FHL2 colocalize in the nucleus and the cytoplasm. A series of confocal images 
of U2OS cells co-expressing YFP-CALM and FLAG-FHL2. YFP-CALM is mainly located in the 
cytoplasm. FLAG-FHL2 is located in both the cytoplasm and nucleus. The confocal line scan shows 
overlapping signal intensity peaks of YFP-CALM and FLAG-FHL2 in the cytoplasm as well as in nuclear 
spots. The green line corresponds to YFP-CALM, red to FLAG-FHL2 and the blue line corresponds to the 
DAPI staining.   
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3.7 Co-localization of CALM/AF10 and FHL2 
In order to examine if FHL2 has an effect on the subcellular distribution of CALM/AF10 
or vice versa, we performed the colocalization experiments with FHL2 and CALM/AF10.  
In initial experiments, we observed that the expression of YFP-CALM/AF10, but not of 
YFP-CALM or of YFP-FHL2, leads to the formation of partial intracellular inclusions 
(fig 3.12). In the cells that co-express YFP-CALM/AF10 and FLAG-FHL2 the 
“speckled” pattern of YFP-CALM/AF10 remains unchanged, however, in addition to its 
normal distribution FLAG-FHL2 appears to be enriched in the cytoplasmic CALM/AF10 
spots (fig 3.14). This co-localization is indicated by yellow color in the merged image 
and by overlapping peak intensities in the line scan (fig 3.14). 
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Figure 3.14 YFP-CALM/AF10 and FLAG-FHL2 co-localize mainly in the cytoplasm. While both 
proteins show their original distribution, with a speckled CALM/AF10 pattern and FHL2 both in the 
nucleus and the cytoplasm, the signals strongly overlap in cytoplasmic spots, seen in yellow color in the 
merged image and overlapping peak intensities in the confocal line scan. The green line corresponds to 
YFP-CALM/AF10, red to FLAG-FHL2 and the blue line corresponds to the DAPI staining.  
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To examine whether the distribution pattern of CALM/AF10 is influenced by the 
relatively large green fluorescent protein (GFP) fluorescent tag (27 kDa) we also used 
another CALM/AF10 expressing construct with a short FLAG-tag to transfect U2OS 
cells. FLAG-CALM/AF10 showed a similar mainly cytoplasmic localization like the 
YFP-CALM/AF10 protein. However, the distribution appears to be slightly more 
homogenous with fewer speckles. This might be due to a more stable protein expression 
or changes in solubility. Furthermore, we did not observe differences in the localization 
of FLAG-FHL2 and YFP-FHL2 when expressed alone. Co-expression of YFP-FHL2 
together with FLAG-CALM/AF10 led to similar results like the co-expression of the 
YFP-CALM/AF10 and FLAG-FHL2  proteins, with co-localization in the cytoplasm (fig 
3.15). Thus we could exclude any major influence of the fluorescent tags on the 
subcellular localization of the proteins we examined. 
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Figure 3.15 FLAG-CALM/AF10 and YFP-FHL2 colocalize in the cytoplasm. Confocal images of 
U2OS cells cotransfected with YFP-FHL2 and FLAG-CALM/AF10. The FLAG-CALM/AF10 is localized 
in the cytoplasm, while YFP-FHL2 is found both in the cytoplasm and in the nucleus. YFP-FHL2 and 
FLAG-CALM/AF10 colocalize in the cytoplasm which is seen in in orange color of the merged image and 
overlapping peak intensities in the confocal line scan. The green line corresponds to YFP-FHL2, red to 
FLAG-CALM/AF10 and the blue line corresponds to the DAPI staining.   
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3.8   Transcriptional activation assays 
After demonstrating that CALM and FHL2 interact both in vitro and in vivo, we asked 
what the functional consequences of this interaction would be. Vecchi et al., (2001) 
reported that CALM activates the transcription of a GAL4 promoter driven luciferase 
reporter gene when fused to the GAL4 DNA-binding domain (GAL4 DBD) in 
mammalian cells. In addition, it is known that FHL2 can act as a co-activator or co-
repressor for a number of transcription factors. In fact, it was shown by Müller et al., 
(2000), that FHL2, when fused to the GAL4 DNA-binding domain, will activate a GAL4 
promoter driven luciferase reporter gene. We therefore used a luciferase reporter gene 
assay to examine the possible functional consequences of FHL2 on CALM-mediated 
transcriptional activation. 
3.8.1 CALM does not activate transcription in a GAL4-based 
transactivation assay 
Figure 3.16 shows a diagram with the possible effects of CALM when activating or 
repressing the transcription of  a luciferase reporter gene. 
 
Figure 3.16 Diagram of CALM in GAL4-based transactivation assay. a) If CALM is an activator of 
transcription the transcription of the luciferase reporter gene is activated. To examine transcriptional 
activation, a reporter plasmid was used in which the luciferase reporter gene was under the control of 5 
GAL4 UAS sites and an SV40 minimal promoter (Gal4-Luc) b) If CALM is a repressor of transcription the 
constitutive expression of the luciferase reporter gene will be reduced. Constitutive expression of the 
luciferase reporter gene is achieved with a reporter plasmid in which the luciferase reporter gene is under 
the control of 5 GAL4 UAS sites and the Herpes Simplex Virus thymidine kinase promoter (Gal4-tk-luc). 
To examine if CALM is a transcriptional activator, CALM together with the GAL4 Luc 
plasmid was transfected into HEK 293T cells. In the plasmid GAL4 Luc, the firefly 
luciferase reporter gene is under the control of 5 GAL4 UAS sites and a GAL4 SV40 
minimal promoter. If CALM is a transcriptional activator the transcription of the 
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luciferase reporter gene is activated. To achieve constitutive expression of the luciferase 
reporter gene and examine if CALM acts as a transcriptional repressor, the Gal4-tk-Luc 
plasmid is transfected into the cells. In the Gal4-tk-Luc plasmid the luciferase reporter 
gene is under the control of 5 GAL4 UAS sites and the Herpes Simplex Virus thymidine 
kinase promoter. If CALM acts as a repressor the transcription the constitutive expression 
of the luciferase reporter gene will be reduced. 
We were unable to reproduce the CALM-mediated transcriptional activation reported by 
Vecchi et al., (2001) and decided not to use GAL4 DBD-CALM for further experiments. 
 
3 Results 
 
 79 
3.8.2 FHL2 acts as transcriptional activator in a GAL4 based 
transactivation assay 
Müller et al., (2000) reported that GAL4 DBD-FHL2 can act as a transcriptional 
activator. Fig 3.17 shows a diagram of this experiment.  
 
Figure 3.17 FHL2 transcription assay model. When GAL4DBD-FHL2 binds to upstream activating 
sequence the transcription of the luciferase reporter gene is activated (Müller et al., 2001). 
GAL4 DBD-FHL2 induced up to 40 fold increase in reporter gene activity in comparison 
to GAL4 DBD alone (Fig 3.18). The positive control, GAL4 DBD-STAT 2, activated the 
transcription of the luciferase reporter gene on average 3520 fold (data not shown). We 
confirmed that FHL2 activates the transcription of the luciferase gene, as reported 
previously. The experiment was performed four times (fig 3.18.)  
 
Figure 3.18 FHL2 fused to GAL4DBD acts as activator of transcription. The GAL4 DBD-FHL2 
activated the transcription of the luciferase up to 40 fold in 293T cells. The cells were transfected with 
GAL4 DBD and GAL4 Luc as negative controls. The positive control, GAL4 DBD-STAT 2, activated the 
transcription of the luciferase reporter gene on average 3520 fold (data not shown). Firefly luciferase 
expression was normalized to Renilla luciferase expression. 
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3.8.3 CALM interferes with the transcriptional activation of GAL4 
DBD-FHL2  
Since we had shown that FHL2 interacts with CALM and can also affect the subcellular 
localization of CALM, we asked whether CALM would affect the transcriptional activity 
of FHL2 (fig 3.19).  
 
Figure 3.19 Model of CALM-FHL2 interaction. The interaction between FHL2 and CALM might affect 
the transcriptional activation of the luciferase reporter gene. 
We could show that GAL4 DBD-FHL2 significantly (up to 40 fold) activates the 
transcription of the luciferase reporter gene (Fig 3.18 and 3.20). Interestingly, when 
GAL4 DBD-FHL2 was cotransfected with YFP-CALM (100 ng, 200 ng and 400 ng) in 
293T cells, the transcriptional activation mediated by GAL4 DBD-FHL2 was reduced by 
about 50% (fig 3.20). These results were very consistent in four independent experiments 
with three measurements per sample. The positive control, GAL4 DBD-STAT 2, 
activated the transcription of the luciferase reporter gene 981 fold (on average, data not 
shown). 
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Figure 3.20 CALM disturbs the activation of GAL4DBD-FHL2. GAL4DBD-FHL2 alone activates the 
transcription of luciferase significantly. Co-transfecting (100 ng, 200 ng and 400 ng) YFP-CALM results in 
significant inhibition of transcriptional activation. The error bars represent standard deviations. 4 
independent experiments with 3 measurements per sample were performed. The positive control, GAL4 
DBD-STAT 2, activated the transcription of the luciferase reporter gene to an average of 981 fold (data not 
shown). Firefly luciferase expression is normalized to Renilla luciferase expression. 
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3.8.4 CALM/AF10 does not affect FHL2 activation 
We then explored the effect of co-expressing YFP-CALM/AF10 on the transcriptional 
activation function of FHL2 (fig 3.22). 
 
Figure 3.21 Model of GAL4-DBD-FHL2 co-transfected with CALM/AF10. If CALM/AF10 has an 
effect on FHL2 the transcription of luciferase gene will be either activated or disturbed 
GAL4 DBD-FHL2 alone activates the transcription of the luciferase reporter gene about 
30 fold. Cotransfection of YFP-CALM/AF10 (100ng, 200 ng and 400 ng) does not affect 
the transcriptional activation of GAL4 DBD-FHL2 (fig 3.22). This is in striking contrast 
to the effect of co-transfecting YFP-CALM which led to a 2 fold reduction of GAL4 
DBD-FHL2 mediated transcriptional activation. 
 
Figure  3.22 YFP-CALM/AF10 does not affect GAL4 DBD-FHL2-mediated transcriptional 
activation in 293T cells. No significant difference between GAL4 DBD-FHL2 alone and GAL4 DBD-
FHL2 co transfected with (100 ng, 200 ng and 400 ng) CALM/AF10 is seen. 
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3.8.5 FHL2 disturbs GAL4DBD-CALM/AF10-mediated transcriptional 
activation 
Since we could show that GAL4 DBD-FHL2 is affected by YFP-CALM but not by YFP-
CALM/AF10, we wondered whether there would be any effect of FHL2 on GAL4 DBD-
CALM/AF10 (figure 3.23). 
 
Figure 3.23 Cartoon of GAL4DBD-CALM/AF10 influenced by FHL2. 
In pilot experiments we determined that GAL4 DBD-CALM/AF10 is indeed an activator 
of transcription of the luciferase reporter gene, leading to a 50-fold activation of 
transcription compared to the expression of GAL4 DBD alone. Interestingly, when a 
FLAG-FHL2 expressing plasmid was cotransfected in this system the transcriptional 
activation of GAL4 DBD-CALM/AF10 was reduced to only 20-fold (fig 3.24). 
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Figure 3.24 Transcriptional activation by GAL4 DBD-CALM/AF10 is disturbed by FLAG-FHL2. A 
clear reduction in transcriptional activation of GAL4 DBD-CALM/AF10 is observed when FLAG-FHL2 is 
cotransfected in 293T cells. Three independent experiments were performed and measured in duplicates. 
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3.9 Expression analysis of the FHL2 protein  
3.9.1 Expression analysis of FHL2 in hematopoietic cell lines 
Western blot analysis was used to examine the expression of the FHL2 protein in 
different hematopoietic cell lines (fig 3.25). High expression of FHL2 was found in the 
human chronic myeloid leukemia in blast crisis (CML) cell line K-562. Lower expression 
of FHL2 can be seen in the human B cell lymphoma cell line Karpas 422 and the Epstein 
Barr-virus (EBV) transformed B-cell cell line LCL 3.1. No FHL2 expression was found 
in DG-75, which is a human Burkitt lymphoma cell line. None of the AML cell lines, T- 
cell lines or the B-cell lines NCEB-1, Jeko-1, Granta 519 and Nalm-6 express FHL2 at 
the protein level (fig 3.25b). 
a)  
b)  
Figure 3.25 Expression of FHL2 in hematopoietic cell lines. a) Strong expression of FHL2 is seen in 
K562, weaker expression in Karpas 422 and LCL 3.1 but no expression in DG-75. In a) 80 µg of protein 
lysate was loaded in each lane. b) No protein expression of FHL2 could be detected in several other cell 
lines. The lysate from 293T cells overexpressing V5-FHL2 was used as a positive control. In b) 100 µg 
protein was loaded in each lane. FHL2 was detected with a mouse monoclonal anti-FHL2 antibody (2.1.13) 
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3.9.2 Expression analysis of FHL2 in normal and solid tumor cell 
lines 
We also examined the expression of FHL2 in cell lines of normal tissue and solid tumors. 
Western blot analysis revealed expression of FHL2 in a cervical cancer cell line (HeLa), 
an osteosarcoma cell line (U2OS) and human embryonic kidney cells (293T). In the 
human lung fibroblast cell line (Wi38) and the osteosarcoma cell line (SaOS) no 
expression of FHL2 could be detected.  
  
Figure 3.26 Western blot analyses of FHL2 in normal and solid tumor cell lines.  FHL2 is expressed in 
HeLa, U2OS, and the 293T cell lines but not in Wi38 or the SaOS cell line. 100 µg protein was loaded in 
each lane and FHL2 was detected with a mouse monoclonal anti-FHL2 antibody. 
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3.9.3 Expression analysis of Fhl2 in rodent cell lines 
Since the monoclonal anti human FHL2 antibody cross-reacts with the mouse and rat 
FHL2 proteins we examined the expression of Fhl2 in several rodent cell lines. For 
expression analyses of murine cell lines 100 µg protein was used and Fhl2 was detected 
with the monoclonal FHL2 antibody (2.1.13). Fig 3.27 shows that the mouse pro B-cell 
(BA/F3) cell line does not express FHL2 in contrast to the mouse embryonic fibroblast 
cell line NIH3T3 and the rat fibroblast cell line TGR which show strong expression. 
 
Figure 3.27 Expression of FHL2 in rodent cell lines. Fhl2 is strongly expressed in a mouse embryonic 
fibroblast cell line (NIH3T3) and in a rat fibroblast cell line (TGR). The murine pro B-cell cell line Ba/F3 
does not express FHL2. As positive control V5-FHL2 expressed in 293T cells was used. 100 µg of protein 
was loaded in each lane. 
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3.10 Expression analysis of FHL2 mRNA in leukemia samples 
3.10.1 Microarray 
We used Affymetrix microarray data to analyze the expression levels of FHL2 in 129 
leukemia patient samples and 10 normal bone marrow samples. The leukemic patient 
samples were from 13 different leukemia subgroups including 10 samples from 
CALM/AF10 positive leukemias. The other leukemias included chronic myeloid 
leukemia (CML), several subtypes of acute myeloid leukemia (AML) and of acute 
lymphoblastic leukemia (ALL). For the analysis of the VSN normalized data set the 
dChip program was used. A comparison of different subtypes of leukemia and normal 
bone marrow revealed a higher expression of FHL2 in CML and in AML samples with 
complex aberrant karyotype (fig 3.28). The expression level of FHL2 was relatively low 
in all the other subgroups examined including the CALM/AF10 positive leukemias. The 
higher expression of FHL2 in CML and AML patients with complex aberrant karyotypes 
did not reach statistical significance at the 0.05 level but suggested a trend, which needs 
to be examined in a larger patient cohort. 
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Figure 3.28 FHL2 is expressed at higher levels in CML (Chronic myeloid leukemia) and AML (Acute 
myeloid leukemia) with complex aberrant karyotype. A microarray analysis was performed on 129 patient 
samples and 10 normal bone marrow samples. Boxplots depicts the mRNA expression levels of FHL2 in 
normal bone marrow (nBM), CML, CALM/AF10 positive leukemias, in 7 different AML subtypes 
(AML_nk: AML with normal karyotype, AML_comp: AML with complex aberrant karyotype, 
AML_MLL: AML with MLL rearrangement, AML_M4: AML with CBFB/MYH11 fusion; AML_M3: 
APL with PML/RARA fusion; AML_M2: AML with AML1/ETO fusion; AML_FLT3: AML with normal 
karyotype and with a FLT3 internal tandem duplication), ALL_Ph: ALL with BCR/ABL fusion; c-ALL: 
(common ALL) and pro-ALL. Expression intensities are depicted on a logarithmic scale.  The box presents 
50% of the dataset and is called the interquartile range (IQR). It is obtained by subtracting the first quartile 
from the third quartile. An expression value was considered to be an outlier when it lies more than 1.5 IQR 
lower or higher than the first or third quartile, respectively. Outliers are represented as circles. The smallest 
and largest values that are not outliers are indicated by a vertical tic mark or "whisker” which are connected 
to the box via a horizontal line. 
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4 Discussion 
The t(10;11)(p13;q14) translocation is a chromosomal abnormality observed in patients 
with acute myeloid and lymphoblastic leukemias (AML and ALL) (Dreyling M. et al., 
1996). The t(10;11)(p13;q14) translocation results in the fusion of CALM on chromosome 
11 band q14 to AF10 on chromosome 10 band p13. The CALM/AF10 fusion protein 
encompasses nearly all the protein domains of both CALM and AF10 (Fig 1.7) (Dreyling 
M. et al., 1996). Deshpande et al. showed that expression of CALM/AF10 induces 
leukemia in a murine bone marrow transplant model (Deshpande A. et al., 2006 ). To 
learn more about CALM/AF10, the physiological functions of CALM and AF10 need to 
be understood. In order to elucidate the function of CALM we searched for CALM 
interacting proteins using a yeast two hybrid screen.  
The CALM-Gene (Clathrin Assembly Lymphoid Myeloid Leukemia Gene) encodes a 652 
amino acid long protein that is ubiquitously expressed and has a high homology with the 
neuronal specific protein AP180. CALM is a clathrin assembly protein and has been 
demonstrated to play an essential role in clathrin-mediated endocytosis (CME). CALM is 
involved in protein-protein and protein-lipid interactions that lead to the stable 
recruitment of clathrin coats (Evans R. and Owen J., 2002; Hinrichsen L. et al., 2006; 
Legendre-Guillemin V. et al., 2004). CALM is involved in two different translocations 
and fusion proteins: the CALM/AF10 and the MLL/CALM. This together with the 
finding that several other endocytic proteins have been identified in leukemia-associated 
gene fusion, suggests that alterations of the CME play a hitherto underappreciated role in 
leukemia development (Bohlander S.K. et al., 2000; Dreyling M. et al., 1996; Floyd S. 
and De Camilli P., 1998; Polo S. et al., 2004; Wechsler D.S et al., 2003).  
4.1 Identification of CALM interacting proteins 
By identifying protein interaction partners of CALM, we would be able to connect 
CALM with cellular pathways and place it in a functional context within the living cell. 
We performed two yeast two hybrid screens using the N-terminal portion of CALM (aa 
1-408) as a bait. In a HeLa cDNA library we identified the following CALM interacting 
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partners: the CALM interacting protein expressed in thymus and spleen (CATS), the 
poly(C)-binding protein 1 (PCBP1), the Tumor susceptibility gene 101 (TSG101) and 
CALM itself. The proteins obtained from the screen of the thymus cDNA library were 
filamin actin binding protein (FLNA), adipocyte fatty acid binding protein 4 (FABP4), 
dipeptidyl-peptidase 7 protein (DPP7) and four and a half LIM domain protein 2 (FHL2).  
4.1.1 CATS 
The CALM interactor CATS was first identified in a previous yeast two hybrid screen of 
our group as a CALM interacting protein. The CATS protein does not contain any known 
conserved protein motifs. The CATS transcript is highly expressed in thymus, spleen and 
colon (Fröhlich-Archangelo L. et al., 2006). From our yeast two hybrid experiment we 
obtained the alternative spliced variant 2 coding for isoform 2 of CATS. The CALM-
CATS interaction had previously been confirmed with GST-pulldown experiment, co-
immunoprecipitation assay as well as in immunofluorescence assay. It is known that the 
localization of a protein is critical for its function. Intriguingly, it was demonstrated that 
in mouse fibroblasts cells (NIH3T3) the presence of CATS can affect the subcellular 
localization of CALM and CALM/AF10. When CATS was coexpressed with 
CALM/AF10, most of the CALM/AF10 protein was drawn to the nucleus. In contrast to 
CALM which shifted only partially to the nucleus upon co-expression with CATS 
(Fröhlich-Archangelo L. et al., 2006). Interestingly, CATS was shown to be highly 
expressed in lymphoid tissues, which indicate that the CATS-CALM interaction might be 
important in CALM/AF10 mediated leukemogenesis. 
4.1.2 PCBP1 
The CALM interactor poly(C)-binding protein 1 (PCBP1) is a member of the PCBP1 
protein family. PCBP1 is characterized by three K-homologous (KH) domains which 
may be involved in RNA binding (Leffers H. et al., 1995). PCBP1 is a RNA binding 
protein that has been shown to be involved in mRNA stabilization, translational 
activation and silencing, and is therefore likely to play a role in a diverse set of post-
transcriptional control pathways (for review see (Makeyev A. and Liebhaber S., 2002). 
Together with the poly(C)-binding protein 2 (PCBP2), PCBP1 functions as translational 
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coactivator of poliovirus RNA (Blyn L.B et al., 1996). PCBP1 has also been implicated 
in the translational control of the human papilloma virus (Collier B. et al., 1998). The 
PCBP1 clone obtained from our yeast two hybrid screen lacks the first KH domain 
completely. Interestingly, PCBP1 has also been shown to interact with CATS (Fröhlich 
Archangelo L., 2006). Thus, it is tempting to speculate that CALM and CATS are 
competing for the binding on PCBP1 or they might form a trimeric complex. Since 
PCBP1 is a shuttling protein (Makeyev A. and Liebhaber S., 2002) it is possible that the 
interaction with CALM might keep PCBP1 in the cytoplasm. Considering the fact that 
CATS completely relocated the CALM/AF10 protein (and not CALM) to the nucleus it is 
tempting to speculate that the CALM/AF10 fusion protein could disrupt the physiological 
function of the CALM-PCBP1 interaction. 
4.1.3 TSG101 
The tumor susceptibility gene 101, which was found to interact with CALM by us, was 
first identified in a screen for potential tumor suppressors (Li L. and Cohen S., 1996). 
TSG101 is an endocytic adaptor protein that has been shown to be crucial in cell 
proliferation, cell survival (Krempler A. et al., 2002), and has a role in the ubiquitin-
controlled endosomal sorting pathways (Bishop N. and Woodman P.G., 2000). Normally, 
TSG101 functions in the cellular vacuolar protein sorting (VPS) pathway, coordinating 
the sorting of membrane associated proteins. This pathway is composed of a series of 
endosomal compartments, and eventually the proteins are delivered to the lysosomes 
(Dupre S. et al., 2001; Piper R. and Luzio J., 2001). Impairment of TSG101 protein 
function disturbs the endosomal trafficking which results for example in prolonged 
signaling of growth factor receptors. This effect is believed to contribute to the 
tumorigenic phenotype exhibited by the TSG101 mutant fibroblasts (Babst M. et al., 
2000).  
The TSG101 clone obtained in our yeast two hybrid screen lacked the N-terminal 
domain. This suggests that only the C-terminal part of TSG101 (aa 280-390) is needed 
for an interaction with CALM. The C-terminal portion of TSG101 which was identified 
in our screen contains part of the putative coiled coil domain (~37 aa), the PTAP motif 
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and the steadiness box (S-Box). It has been shown that the expression of the C-terminal 
fragment of TSG101 blocks the budding of PTAP- and PPPY dependent retroviruses like 
HIV (Johnson M. et al., 2005). Depletion or overexpression of TSG101 arrested or 
decreased the release of HIV-1, thereby functionally linking TSG101 to virus budding 
and release (Demirov D.G. et al., 2002; Garrus et al., 2001).  
Clathrin-coated vesicles mediate endocytosis of transmembrane receptors and the 
transport of newly synthesized lysosomal hydrolases from the trans-Golgi network 
(TGN) to the lysosomes (Schmid S., 1997). Clathrin and various adaptor protein 
complexes play also an important role in shaping the budding vesicles as well as in the 
packaging of cargo (Ritter B. and McPherson P.S., 2004). This demonstrates that protein 
sorting and vesicle budding are functionally integrated. Interestingly, clathrin has been 
described as the major binding partner of CALM. After overexpressing CALM, 
inhibition of endocytosis and disruption of clathrin localization in the TGN was observed. 
This resulted in perturbance in the TGN-endosome trafficking (Tebar F. et al., 1999).  
Despite the unknown biological function of the CALM-TSG101 interaction, it is quite 
apparent that these two proteins are involved in the same pathways, including the 
endosomal sorting pathway. Thus, it is conceivable that the CALM/AF10 fusion protein 
might disrupt the endosomal sorting pathway through protein relocalization. 
4.1.4 CALM 
The CALM gene was first identified as fusion partner of AF10 in the t(10;11)(p13;q14) 
translocation, which was observed in acute myeloid leukemia (AML), acute 
lymphoblastic leukemia (ALL) and malignant lymphoma (Dreyling M.H. et al., 1998). 
We identified CALM as a CALM interacting protein suggesting that CALM might 
dimerize or multimerize with itself. The prey clone of CALM which we obtained in our 
yeast two hybrid screened lacked the first 114 amino acids. The biological function of 
CALM dimerization or multimerization is still unknown and remains to be explored. 
4.1.5 FLNA 
The CALM interactor FLNA is a homodimeric F-actin crosslinker organizing actin 
filaments in parallel arrays or three dimensional webs linking them to the cell membrane 
4 Discussion 
 
 94 
(Gorlin J. et al., 1990 ). FLNA contributes to the stability of the membrane by anchoring 
membrane proteins to the actin cytoskeleton. There is increasing evidence that FLNA 
also plays a role in the regulation of nuclear functions. Previous findings indicate that 
FLNA is processed by proteolysis. The proteolytic products of FLNA seem to play a role 
as signaling molecules integrating nuclear and cytosolic pathways (Garcia E. et al., 2006; 
Uribe R. and Jay D., 2007). Our FLNA prey clone contained only the C-terminal part (aa 
2306 - 2595) of FLNA. FLNA and the adapter protein complex 2 (AP-2) are competing 
for the binding sites on the prostate specific membrane antigen (PSMA) (Rajasekaran A. 
et al., 2005). Interestingly, CALM has also been shown to interact with AP-2 (Owen D. 
and Luzio P., 2000). It has been suggested that the dissociation of FLNA facilitates the 
binding of AP-2 to PSMA (Ghosh A. and Heston W., 2007). PSMA is then endocytosed 
via CME (Hinrichsen L. et al., 2006; Rajasekaran A. et al., 2005). Depletion of AP-2 
weakens the association between CALM and the plasma membrane (Meyerholz A. et al., 
2005). It is therefore possible that the detached CALM relocates to the spot where the 
endocytic cycle starts. The exact function of the CALM-FLNA interaction in this 
complicated process remains to be explored. 
4.1.6 FABP4 
Adipocyte fatty acid binding protein (FABP4) is a member of the intracellular fatty acid 
binding protein (FABP) family. It plays a role in lipid metabolism, fatty acid uptake, 
transport, metabolism and homeostasis in adipocytes (Michal J. et al., 2006). For the 
CALM-FABP4 interaction the C-terminal part (aa 36-153) of FABP4 seems to be 
required, since this portion of FABP4 was contained in our prey clone. The biological 
function of CALM-FABP4 interaction is unknown. One possibility is that CALM has an 
unknown role in the regulation of lipids and glucose homeostasis. 
4.1.7 DPP7 
Dipeptidyl-peptidase 7 protein (DPP7) is a post-proline cleaving aminopeptidase 
expressed in quiescent lymphocytes. These quiescent lymphocytes are protected from 
programmed cell death by a cellular program that suppresses apoptosis. Downregulation 
of DPP7 inhibits the suppression of the apoptosis and resting lymphocytes become active 
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(Chiravuri M. et al., 1999). Our DPP7 prey clone lacks the first 130 amino acids. The 
interaction between CALM and DPP7 suggest a possible role of CALM in the regulation 
of quiescence of lymphocytes. The leukemogenic CALM/AF10 fusion protein might 
disrupt the function of DPP7 for example through relocalization. The CALM-DPP7 
interaction might thus play an important role in CALM/AF10-mediated leukemogenesis. 
4.2 FHL2 
We chose to examine the interaction between CALM and the four and a half LIM protein 
2 (FHL2) in more detail. FHL2, also called DRAL for Downregulated in 
Rhabdomyosarcoma LIM protein, was first identified because of its differential 
expression between normal human myoblasts and their malignant counterparts, the 
rhabdomyosarcoma cells (Genini M. et al., 1997). The FHL2 protein is composed of 4 
complete LIM domains and a half LIM domain at its N-terminus (figure 4.1).  
LIM is an acronym for Lin-11, Isl-1 and Mec-3 which are the first three proteins in which 
the LIM motif was found (Freyd G. et al., 1990; Karlsson O. et al., 1990; Way J. and 
Chalfie M., 1988). LIM domains are characterized by a highly conserved double zinc 
finger motif. The cysteine and histidine residues bind two zinc atoms as shown in figure 
4.1 (Michelsen J.W. et al., 1993; Schmeichel K.L. and Beckerle M.C., 1997). 
         
Figur 4.1 Domain structure of the FHL2 protein. FHL2 is composed of 9 zinc fingers in total. Note that 
the half LIM domain on N-terminus contains just one zinc finger. One LIM domain consists of two zinc 
fingers. Zinc atoms (grey spheres) in the middle, are bound by the cystein and histidine residues (yellow). 
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The FHL2 prey clone isolated from our yeast two hybrid assay contains the complete 
coding sequence of the FHL2 protein. The FHL2 gene is located on chromosome 2 band 
q12-q13 and encodes a protein of 279 amino acids (Chan K. et al., 1998).  
FHL2 is a protein interacting with many different proteins belonging to diverse functional 
classes including steroid receptors like estrogen receptor alpha (ERalpha), androgen 
receptor (AR), integrin receptor a7ß1, structural proteins, signal transducers, transcription 
factors and cofactors, splicing factors, DNA replication-, repair- and diverse other 
enzymes (Kobayashi S. et al., 2004; Müller J. et al., 2000; Samson T. et al., 2004).  
 
Intriguingly, it has been shown that transcription of the FHL2 gene can be stimulated by 
p53. P53 induces FHL2 expression during apoptosis (Scholl F. et al., 2000). p53 
mutations or deletions are found in nearly all tumor types. It is estimated that they can be 
found in more than 50% of all cancers (Berkson R. et al., 2005). In addition, it has been 
observed that increased nuclear FHL2 expression correlates with progression to a highly 
malignant phenotype in prostate carcinoma (Müller J. et al., 2002). Strong nuclear FHL2 
immunoreactivity was also observed in lung tumor biopsies, while no FHL2 was detected 
in healthy lung tissue (Borczuk A. et al., 2004). Compared to normal tissue, elevated 
expression of FHL2 was also detected in human epithelial ovarian cancer (Gabriel B. et 
al., 2004). In expression analyses, FHL2 mRNA levels were increased in patients with 
AML-FAB M7 subtype, compared to other AML’s (Lotem J. et al., 2005). The finding of 
increased expression of FHL2 in various types of cancers made it an interesting candidate 
for further characterization.  
4.2.1 FHL2 interacts with CALM and influences the subcellular 
localization of CALM 
The CALM and FHL2 interaction was confirmed in a GST pulldown assay and was 
further corroborated in vivo by co immunoprecipitation. We showed that the full length 
FHL2 was necessary for the CALM-FHL2 interaction to take place. The FHL2 
interacting domain in CALM was determined to be between amino acids 294 and 335. 
Interestingly, FHL2 binds to β-integrin (Samson T. et al., 2004), which together with 
clathrin, a major binding partner of CALM, has been shown to be involved in endocytosis 
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of bacteria (Tebar F. et al., 1999; Van Nhieu G.T. et al., 1996). This suggests a possible 
role for the CALM–FHL2 interaction in the complex interaction network of endocytosis. 
The hypothesis that FHL2 and CALM act together in the cytoplasm in the endocytic 
machinery is supported by the fact that expression of YFP-CALM and FLAG-FHL2 in 
U2OS cells result in co-localization of both proteins in the cytoplasm and at the cell 
membrane. In addition, there was also co-localization of FHL2 and CALM in the nucleus 
of the U2OS cell when CALM and FHL2 were cotransfected, suggesting a nuclear 
function for these proteins.  
FHL2 has previously been shown to localized to both the nucleus and the cytoplasm (Hill 
A. and Riley P., 2004; Labalette C. et al., 2004; Scholl F. et al., 2000). We performed 
immunofluoroscence experiments with YFP tagged CALM/AF10 and FLAG tagged 
FHL2 to examine the possible colocalization of FHL2 with CALM/AF10. However, the 
cells expressing the YFP-CALM/AF10 protein formed inclusion bodies of YFP-
CALM/AF10 making it difficult to interprete the results. The same experiments were 
performed using YFP tagged FHL2 and FLAG tagged CALM/AF10. These experients 
revealed FLAG-CALM/AF10 mainly in the cytoplasm while FHL2 was predominantly 
seen in the nucleus. A minor fraction of the FHL2 co-localized with CALM/AF10 in the 
cytoplasm. It could be shown by several investigators that increased nuclear FHL2 
expression correlates with progression to a highly malignant phenotype of prostate 
carcinoma, lung tumor and human epithelial ovarian cancer (Borczuk A. et al., 2004; 
Gabriel B. et al., 2004; Müller J. et al., 2002). Overexpression of FHL2 has also been 
observed to induce apoptosis in human rhabdomyosarcoma  (RD) cells, transformed 
monkey kidney (COS-1) cells, and normal mouse fibroblast (NIH 3T3) cells (Scholl F. et 
al., 2000).  
When fused to the GAL4 DNA binding domain (GAL4-DBD), FHL2 is activating the 
transcription of the luciferase reporter gene (Müller J. et al., 2000). We could show that 
CALM co transfected with GAL4-DBD-FHL2 significantly disturbed the transcriptional 
activation induced by FHL2. Since the FHL2 interaction domain on CALM is present in 
the CALM portion of the leukemogenic CALM/AF10 we also tested whether 
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CALM/AF10 would influence the transcriptional activation function of GAL4 DBD-
FHL2. Surprisingly, this was not the case. The fact that the transcriptional activation 
mediated by FHL2 was inhibited by CALM but not by CALM/AF10 could mean that in 
the presence of the CALM/AF10 fusion protein the normal negative regulatory role of 
CALM on FHL2 is reduced thereby increasing the tumor promoting activity of FHL2.  
Since Vecchi et al., had shown that a GAL4-DBD-CALM fusion acts as a transcriptional 
activator in a reporter gene assay we were interested to see which influence the co-
expression FHL2 would have in this system (Vecchi M. et al., 2001). However, we were 
unable to reproduce the results of Vecchi et al. Intrestingly, we were able to show that a 
GAL4-DBD-CALM/AF10 fusion behaved as a potent transcriptional activator in our 
reporter gene assays. Co transfection of FHL2 and GAL4 DBD-CALM/AF10 led to a 
marked reduction of the CALM/AF10-mediated transcriptional activation of the 
luciferase reporter gene. In contrast, there was no influence of CALM/AF10 on the 
transcriptional activiation mediated by GAL4 DBD-FHL2. One explanation for this lack 
of influence could be that CALM/AF10, being a protein of about 170 kDa, is expressed at 
a much lower molarity than the small FHL2 protein (~ 33 kDa). The CALM/AF10 would 
therefore not be able to effectively bind to and influence the much more abundant GAL4 
DBD-FHL2. On the other hand, when GAL4-DBD-CALM/AF10 is expressed, the FHL2 
protein binds to all the GAL4-DBD-CALM/AF10 protein molecules thus inhibiting or 
quenching the transcription induced by CALM/AF10. Another explanation might be that 
the CALM interacting domain of FHL2 is masked when FHL2 is fused to the GAL4-
DBD protein. 
4.2.2 FHL2 is expressed in tumor cell lines  
FHL2 has been shown to be expressed in heart (Kong Y. et al., 2001; Müller J. et al., 
2000; Scholl F. et al., 2000), brain, liver, lung (Tanahashi H. and Tabira T., 2000), human 
skeletal muscle (Genini M. et al., 1997; Morgan MJ. , 1996), as well as in human 
osteoblasts (Chu P. et al., 2000). In expression analyses of different normal and tumor 
cell lines, we observed FHL2 expression in the cervical cancer cell line HeLa, the 
osteosarcoma cell line U2OS and the human embryonal kidney cell line 293T. No 
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expression was seen in the human lung fibroblast cell line Wi38 and the osteosarcoma 
cell line SaOS. It has been shown that enhanced levels of p53 stimulate the expression of 
FHL2 (Johannessen M. et al., 2006), conversely one would expect very low levels of 
FHL2 in cells with low p53 expression. Since the osteosarcoma cell line SaOs does not 
express p53 this might be the explanation for the absence of FHL2 expression in this cell 
line. Expression of FHL2 has been observed in the MRC-5 cell line, which is a normal 
lung fibroblast cell line (Tanahashi H. and Tabira T., 2000). Therefore we expected to see 
expression of FHL2 in the normal lung fibroblast cell line Wi38 but in our experiments 
no FHL2 expression was detected. The Wi-38 cell line was derived from a female fetus 
of about 3 months gestational age while the MRC-5 cell line is derived from a 14 week 
male fetus. We thus lack a possible explanation for the absence of FHL2 in Wi38 cells. 
Expression studies on rodent cell lines revealed strong expression of FHL2 in the mouse 
embryonic fibroblast cell line NIH3T3 and the rat fibroblast cell line TGR. No FHL2 
expression was detected in the murine pro B cell line Ba/F3. Except for the EBV-
transformed B-cell cell line LCL 3.1, no expression of FHL2 could be detected in human 
B-cell cell lines . None of the T-cell nor AML cell lines were showing any expression of 
the FHL2. FHL2 expression was observed in the B-cell lymphoma cell line Karpas 422 
and the BCR/ABL expressing CML cell line K562. The explanation for the expression of 
FHL2 in K562 cells might be that these cells express the BCR-ABL fusion gene. It has 
been reported that expressing BCR-ABL in Ba/F3 cells resulted in an increased 
expression of the p53 (Wendel H-G. et al., 2006). In addition, it was shown that p53 can 
stimulate the expression of FHL2 (Scholl F. et al., 2000). Combining these findings 
suggest the following picture: BCR/ABL induces the expression of p53 in K562 cells, 
which in turn stimulates the expression of FHL2. The fact that the cell lines Karpas 422 
and LCL 3.1 also express p53 and FHL2 supports this conclusion. 
4.2.3 FHL2 is highly expressed in CML and AML with complex 
aberrant karyotypes 
We also analyzed the expression levels of FHL2 in a series of cytogenetically and 
genetically well-characterized AML, ALL and CML samples for which Affymetrix 
micro-array expression data were available. Interestingly, the results from the K562 cell 
4 Discussion 
 
 100 
line that FHL2 expression might be high in CML were also mirrored in the patient 
samples. FHL2 showed higher expression in CML patients and patients with AML with 
complex aberrant karyotypes compared to other leukemia subgroups. However, the 
standard deviations of the FHL2 expression levels in the CML and complex aberrant 
AML leukemia subgroups were quite high. This might indicate that these groups are 
heterogeneous with respect to their FHL2 expression levels (containing subgroups of 
FHL2 high and low expressions). An alternative explanation for this observation is the 
fact that we only examined a very small number of patient samples in each group (n = 
10).  
One of the characteristics of AML with complex aberrant karyotypes is the frequent loss 
of chromosome 5 as well as a high incidence of TP53 deletions and/or mutations 
resulting in an overall unfavorable prognosis (Schoch C. et al., 2002). Interestingly, Qian 
et al. showed that therapy related myelodysplastic syndrome (t-MDS) and acute myeloid 
leukemia (t-AML) characterized by a loss of a whole chromosome 5 or a deletion of the 
long arm of chromosome 5 (-5/del(5q)) showed elevated FHL2 expression levels (Qian 
Z. et al., 2005). These issues need to be addressed by analyzing the FHL2 expression in a 
larger number of patients with CML and AML with complex aberrant karyotypes (with 
and without -5/del(5q)).  
If the expression levels of FHL2 are significantly different in these leukemia subgroups it 
might even be possible to use FHL2 as a marker for these groups. These observations are 
also consistent with the fact that a high FHL2 expression in solid tumors is associated 
with an adverse prognosis. 
FHL proteins have been described as coregulators of transcription by integrating the 
activity of different transcription factors (Fimia GM. et al., 2000; Johannessen M. et al., 
2006). Despite their structural similarity, they seem to have evolved specialized functions 
by regulating distinct transcription factors (Fimia G-M. et al., 2000). Interestingly, it was  
recently shown that another member of the FHL family, FHL1, plays a role in AML 
prognosis. High expression of FHL1 correlated with a poor prognosis in cytogenetically 
normal AML (Metzeler K. et al., 2007). Intriguingly, FHL1 was found to be 
overexpressed in MLL wild type versus MLL knock out cells (Schraets D. et al., 2003). It 
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was shown that the homeobox gene HOX11 is a transcriptional regulator for FHL1 (Rice 
KL. et al., 2008). HOX11 has also been implicated to function as an oncogenic 
transcriptional activator in leukemogenesis (Zhang N. et al., 1996). Together these 
findings suggest a hitherto underappreciated role of four and a half LIM domain proteins 
in leukemogenesis.  
4.3 Possible mechanisms of CALM/AF10-mediated leukemogenesis 
It is intriguing to speculate that the dimerization potential of CALM plays a critical role 
in the malignant transformation potential of the CALM/AF10 fusion protein. The mixed 
lineage leukemia gene (MLL) is involved in more than 50 chromosomal translocations 
associated with human acute leukemias (Popovic R. and Zeleznik-Le N.J., 2005). One of 
the chromosomal translocations involving MLL is the MLL-AF10 translocation. MLL-
AF10 was found in AML (Chaplin T. et al., 1995). It is known that certain MLL fusion 
proteins dimerize and then bind to DNA, and that the dimerization domains are supplied 
by the fusion partner. It is thus conceivable that the dimerization domain provided by 
CALM is very critical in the malignant transformation mediated by the CALM/AF10 
fusion protein. 
Alternatively, the critical domain supplied by the CALM moiety in the CALM/AF10 
fusion protein might be the transcriptional activation domain of CALM. A transcriptional 
activation domain could be mapped to the C-terminal portion of the CALM protein which 
is also contained in the CALM/AF10 fusion protein. This activation domain mapping of 
CALM was performed in the yeast system. In our hands, however, this transcriptional 
activation domain of CALM was not very apparent in mammalian cells (luciferase 
reporter assays). An argument against CALM developing the same transcriptional 
activity in CALM/AF10 fusions as MLL in the MLL/AF10 fusion is the structural 
difference between CALM and MLL. In contrast to CALM, which lacks DNA binding 
domains, the N-terminal of MLL has two DNA binding domains: the AT hook motifs and 
the DNA methyltransferase homology region. These two domains guide MLL to the 
specific chromosomal sites. (Martin M.E. et al., 2003; Slany R., 2005). The C-terminal 
domain of CALM has been described to behave as a long fishing line (Evans R. and 
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Owen J., 2002). We propose that CALM dimerization occurs when these “fishing lines” 
anchor to each other thus providing a platform for recruitment of additional clathrin 
assembly proteins and proteins involved in endocytosis and membrane trafficking. In the 
presence of the CALM/AF10 fusion this platform normally provided by CALM might be 
disturbed. 
However, we can not exclude that CALM/AF10 also leads to a disruption of normal 
AF10 function. AF10 has a Drosophila homologue called Alhambra that has been shown 
to regulate transcription through Polycomb group-responsive elements (PREs) (Perrin L. 
et al., 2003). These elements maintain transcriptional decisions to ensure correct cell 
identity during development and differentiation. Together with the findings that AF10 is 
a putative transcription factor it is possible that a disruption of AF10 function by 
CALM/AF10 leads to a transcriptional deregulation of the many genes that are regulated 
by polycomb and trithorax complexes. Interestingly, in support of this idea we and others 
could show that CALM/AF10 fusion-positive patients show overexpression of the 
polycomb group gene BMI1, the homeobox gene MEIS1 and the HOXA cluster genes, 
(Caudell D. et al., 2007; Krause A. et al., 2004). In addition, it was shown that patients 
with MLL rearrangements had a very similar HOX expression pattern as CALM/AF10 
positive patients (Krause A., 2006). The important role of HOX genes in acute leukemias 
is well established (Bergeron J. et al., 2006; Rice K. and Licht J.D., 2007; Soulier J. et al., 
2005; Thorsteinsdottir U. et al., 2001).  
A structure/function analysis of AF10 in the leukemogenic fusion proteins MLL/AF10 
and CALM/AF10 showed that the octapeptide motif (OM) and the leucine zipper (LZ) of 
AF10 are required for malignant transformation mediated by both proteins (DiMartino 
JF. et al., 2002; Okada Y. et al., 2005). Interestingly, the AF10 interaction domain for the 
lymphoid transcriptional regulator Ikaros was mapped to the OMLZ domain of AF10, 
suggesting an important role of Ikaros in CALM/AF10 and MLL/AF10 induced 
leukemias (Greif P. et al., 2007). AF10 has also been shown to interact with the histone 
methyl transferase DOT1L (disruptor of telomeric silencing 1), as well as with the 
GAS41 which is a component of the chromatin remodeling complex (Debernardi S. et al., 
2002; Okada Y. et al., 2005).  
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Alternatively to disrupting the normal AF10 function, the CALM/AF10 fusion protein 
might mediate some of its effects by using the AF10 moiety to disrupt other cellular 
functions. It was shown that CATS can recruit the CALM/AF10 fusion protein to the 
nucleolus. It is thus possible that the AF10 portion of CALM/AF10 might affect the 
function of nucleolar proteins (Fröhlich-Archangelo L. et al., 2006). Nucleolar proteins 
regulate cell proliferation and growth by ribosome biogenesis and are very important in 
controlling p53 function (Horn H. and Vousden K., 2004; Maggi l. and Weber J., 2005; 
Olson MO., 2004; Rubbi CP. and Milner J., 2003). Deregulation of these mechanisms is 
the key event in the initiation and progression of malignant transformation (Horn H. and 
Vousden K., 2004; Lohrum M. and Vousden K., 2000).  
It has become clear during the course of this discussion that there are many different 
possible mechanisms by which CALM/AF10 might induce leukemogenesis. The careful 
dissection of CALM/AF10 protein interactions, like the CALM-FHL2 interaction, will 
provide new entry points for unravelling the complicated mechanisms which are 
responsible for the leukemogenic potential of the CALM/AF10 fusion protein. 
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5 Summary 
The Clathrin Assembly Lymphoid Myeloid gene (CALM) was first found in the fusion 
gene CALM/AF10 as the fusion partner of AF10 resulting from the t(10;11)(p13;q14)-
translocation. The CALM/AF10 fusion protein has been shown to play a crucial role in 
CALM/AF10 associated leukemogenesis. In order to gain insight into the function of 
CALM yeast two hybrid screens of HeLa and Thymus cDNA library were performed 
using the N-terminal half of CALM as bait. Eight different putative CALM interacting 
proteins were obtained including the four and a half LIM domain protein (FHL2). The 
interaction between CALM and FHL2 was confirmed with co-immunoprecipitation, GST 
pulldown assay and colocalization experiments. The FHL2 interaction domain in CALM 
was mapped to amino acids 294 to 335. This domain is also contained in the 
CALM/AF10 fusion protein.. Luciferase reporter gene assays were performed to analyze 
the effect of FHL2, CALM and CALM/AF10 on each other as transcriptional regulators. 
Interestingly we could show that the GAL4DBD-FHL2-induced activation of 
transcription was inhibited when CALM was coexpressed, and that the GAL4DBD-
CALM/AF10-induced activation of transcription was strongly inhibited by FHL2. 
Western blot analyses showed no expression of FHL2 in any of the AML, T-cell and B-
cell cell lines tested except for the EBV-transformed B-cell cell line L.C.L 3.1 and the B-
cell lymphoma cell line Karpas 422. FHL2 was highly expressed in cervical cancer, 
osteosarcoma and CML cell lines. Micro array analyses of FHL2 expression levels in 139 
leukemia and normal bone marrow samples showed that FHL2 is highly expressed in 
CML and in AML complex aberrant karyotypes. The inhibitory function of CALM on 
FHL2 in our reporter gene assays as well as the high expression levels of FHL2 in CML 
and AML with complex aberrant karyotypes suggests that FHL2 might play an important 
role in leukemogenesis not only in CALM/AF10 positive leukemias but also in a broader 
spectrum of leukemias. 
The identification of the CALM-FHL2 interaction provides an interesting new entry point 
to dissect the mechanisms by which the CALM/AF10 fusion protein mediates 
leukemogenesis.
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6 Zusammenfassung 
Das Clathrin Assembly Lymphoid Myeloid Gen (CALM) wurde zuerst als Fusionspartner 
von AF10 in dem Fusionsgen CALM/AF10, bei der t(10;11)(p13;q14) Translokation 
entdeckt.. Das CALM/AF10 Fusionsprotein spielt eine entscheidende Rolle in der 
CALM/AF10 assoziierten Leukämieentstehung. Um einen Einblick in die Funktion von 
CALM zu erlangen, sind Yeast Two Hybrid Screens von HeLa und Thymus cDNA 
Bibliotheken mit der N-terminalen Hälfte von CALM als Köder durchgeführt worden. 
Dabei konnten acht potentielle CALM Interaktionspartner identifiziert werden, 
einschlieβlich des four and a half LIM domain Proteins (FHL2). Die Interaktion zwischen 
CALM und FHL2 wurde durch Koimmunopräzipitations-, GST-pulldown- und 
Kolokalisationsexperimente bestätigt. Die FHL2 Interaktionsdomäne von CALM wurde 
den Aminosäuren 294 bis 335 zugeordnet. Diese Domäne ist auch in dem CALM/AF10 
Fusionsprotein enthalten. Die Expression von FHL2 führt zu einer Anreicherung von 
CALM in dem Zellkern, aber die vorwiegend zytoplasmatische Lokalisation von dem 
leukämischen Fusionsprotein CALM/AF10 wird nicht beeinflusst. Um den Einfluss von 
FHL2, CALM und CALM/AF10 aufeinander als Transkriptionsregulatoren zu 
analysieren, sind  Luciferase Reportergenexperimente durchgeführt worden. Die 
Ergebnisse zeigen eine Hemmung der GAL4DBD-FHL2-induzierten 
Transkriptionsaktivierung durch gleichzeitige Expression von CALM. Ebenso wurde die 
GAL4DBD-CALM/AF10-induzierte Transkriptionsaktivierung stark durch  
Koexpression von FHL2 gehemmt. Western-Blot Analyse zeigt, dass FHL2 in weder in 
AML, noch in T- oder B-zell Zelllinien experimiert wird. Exprimiert wird FHL2 
hingegen in der EBV-transformierten B-Zell Zelllinie L.C.L 3.1, in der B-Zell Lymphom 
-Zelllinie Karpas 422 exprimiert sowie in den Cervixkarzinom-, Osteosarkom- und CML-
Zelllinien. Die Micro Array Analyse von dem FHL2 Expressionsniveau in 139 Proben 
von Leukämiepatienten und normalen Knochenmark zeigen auf, dass FHL2 in AML mit 
komplexem Karyotyp sowie in  CML hochexprimiert ist.  
 
Sowohl die hemmende Funktion von CALM auf FHL2 in unserem 
Reportergenexperiment, als auch das hohe Expressionsniveau von FHL2 in CML und 
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AML mit komplexem Karyotyp, deuten an, dass FHL2 nur bei der Leukämieentstehung 
in CALM/AF10 positiven Leukämien sondern auch in einem breiteren Spektrum von 
hämatologischen Tumoren eine wichtige Rolle spielt. 
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